PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3143744-5 1988 After 3 h of insulin infusion, basal [Ca2+]i rose to 234 +/- 21 nM, but the responses to insulin and glyburide were completely abolished. Glyburide 101-110 insulin Homo sapiens 13-20 3133266-7 1988 Addition of glibenclamide to insulin resulted in a further reduction of the fasting plasma glucose (7.9 +/- 0.5 mmol/l) and HbA1 (8.3 +/- 0.2%) concentration whereas the basal (0.21 +/- 0.03 nmol/l) and glucagon-stimulated C-peptide concentrations (0.34 +/- 0.06 nmol/l) increased again. Glyburide 12-25 insulin Homo sapiens 29-36 3149105-1 1988 Insulin binding to erythrocyte receptors was studied in 36 newly diagnosed male subjects with NIDDM, treated with diet alone (Group I; n = 10) or diet + glibenclamide (Group II; n = 12) or diet + glibenclamide + metformin (Group III; n = 14). Glyburide 153-166 insulin Homo sapiens 0-7 3149105-1 1988 Insulin binding to erythrocyte receptors was studied in 36 newly diagnosed male subjects with NIDDM, treated with diet alone (Group I; n = 10) or diet + glibenclamide (Group II; n = 12) or diet + glibenclamide + metformin (Group III; n = 14). Glyburide 196-209 insulin Homo sapiens 0-7 3147830-0 1988 In vivo action of glibenclamide in obese subjects with mild type 2 (non-insulin dependent) diabetes. Glyburide 18-31 insulin Homo sapiens 72-79 3133266-9 1988 The daily insulin dose could be reduced by 25% after addition of glibenclamide to insulin, while it remained unchanged when insulin was combined with placebo. Glyburide 65-78 insulin Homo sapiens 10-17 3133266-9 1988 The daily insulin dose could be reduced by 25% after addition of glibenclamide to insulin, while it remained unchanged when insulin was combined with placebo. Glyburide 65-78 insulin Homo sapiens 82-89 3133266-9 1988 The daily insulin dose could be reduced by 25% after addition of glibenclamide to insulin, while it remained unchanged when insulin was combined with placebo. Glyburide 65-78 insulin Homo sapiens 82-89 3119405-9 1987 The results indicate that the glycemic effect of glyburide represents enhancement of insulin action and occurs independently of membrane insulin receptors. Glyburide 49-58 insulin Homo sapiens 85-92 3126626-0 1988 Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy. Glyburide 0-13 insulin Homo sapiens 39-46 3126626-5 1988 This was observed in spite of the fact that the daily insulin dose was reduced by approximately 30% in the glibenclamide-treated group of patients. Glyburide 107-120 insulin Homo sapiens 54-61 3126626-6 1988 It is concluded that in NIDDM patients with second failure to glibenclamide ot glipizide therapy, the responsiveness to glibenclamide may be at least partially restored by a short period of insulin treatment. Glyburide 120-133 insulin Homo sapiens 190-197 3140992-0 1988 The effects of glibenclamide treatment on insulin secretion and on insulin binding to erythrocytes in type II diabetes mellitus. Glyburide 15-28 insulin Homo sapiens 42-49 3126291-2 1988 A system approach to the analysis of pharmacodynamic systems is applied to the relationship between the glyburide serum concentration (Cd) and a resulting pharmacologic effect response, that is, the C-peptide serum concentration (Cc) in patients with non-insulin dependent diabetes mellitus (NIDDM). Glyburide 104-113 insulin Homo sapiens 199-208 3119407-0 1987 Glyburide modulates insulin-mediated locomotor response of confluent cell cultures to wounding. Glyburide 0-9 insulin Homo sapiens 20-27 3119407-4 1987 Glyburide enhanced the effect of insulin on both parameters of the locomotor response and also sensitized the cells to a previously ineffective concentration of insulin (10(-12) M). Glyburide 0-9 insulin Homo sapiens 33-40 3119407-4 1987 Glyburide enhanced the effect of insulin on both parameters of the locomotor response and also sensitized the cells to a previously ineffective concentration of insulin (10(-12) M). Glyburide 0-9 insulin Homo sapiens 161-168 3117609-7 1987 During the hyperglycemic-clamp studies performed in normal subjects, both GB and GZ increased the first- (1.6-fold) and second- (2.2-fold) phase plasma insulin responses more than hyperglycemia alone. Glyburide 74-76 insulin Homo sapiens 152-159 2894389-1 1987 The acute effect of glibenclamide, a hypoglycemic sulfonylurea, upon transglutaminase activity was investigated in 6 type II diabetic patients by perfusing 1 mg glibenclamide during 1 h. Blood samples were drawn 0, 10, 20, 30, 60 min during and 30 and 60 min after perfusion to determine insulin, glucose and transglutaminase activity. Glyburide 20-33 insulin Homo sapiens 288-295 3126223-0 1987 Effects of metformin and glibenclamide on insulin receptors in fibroblasts and tumor cells in vitro. Glyburide 25-38 insulin Homo sapiens 42-49 3126223-1 1987 The effects of the oral hypoglycemic agents metformin and glibenclamide on receptor binding of insulin and insulin-induced receptor down-regulation were studied in cultured normal human fibroblasts, human breast tumors (cell lines MCF-7 and T-47D) and a human colon tumor (cell line HCT-8) in order to identify differences in receptor regulation between normal and transformed cells. Glyburide 58-71 insulin Homo sapiens 95-102 3126223-1 1987 The effects of the oral hypoglycemic agents metformin and glibenclamide on receptor binding of insulin and insulin-induced receptor down-regulation were studied in cultured normal human fibroblasts, human breast tumors (cell lines MCF-7 and T-47D) and a human colon tumor (cell line HCT-8) in order to identify differences in receptor regulation between normal and transformed cells. Glyburide 58-71 insulin Homo sapiens 107-114 3126223-3 1987 Glibenclamide (2 microM) and metformin (1-10 microM) induced a 13-28% reduction in insulin receptor down regulation in fibroblasts exposed to 1.7 x 10(-8)M-insulin, the loss of binding on exposure to insulin decreasing from 55% to 40-48%. Glyburide 0-13 insulin Homo sapiens 83-90 3126223-3 1987 Glibenclamide (2 microM) and metformin (1-10 microM) induced a 13-28% reduction in insulin receptor down regulation in fibroblasts exposed to 1.7 x 10(-8)M-insulin, the loss of binding on exposure to insulin decreasing from 55% to 40-48%. Glyburide 0-13 insulin Homo sapiens 156-163 3117609-10 1987 In both NIDDM and control subjects, the effects of hyperglycemia and sulfonylurea drugs (both GB and GZ) on the first- and second-phase plasma insulin responses were simply additive. Glyburide 94-96 insulin Homo sapiens 143-150 3123184-8 1987 Insulin sensitivity, assessed by an insulin tolerance test, was more improved with glyburide than with glipizide. Glyburide 83-92 insulin Homo sapiens 0-7 3123184-8 1987 Insulin sensitivity, assessed by an insulin tolerance test, was more improved with glyburide than with glipizide. Glyburide 83-92 insulin Homo sapiens 36-43 3116364-5 1987 Glyburide increased sensitivity to insulin (ie, shifted the dose-response curve to the left) without affecting either responsiveness or insulin binding. Glyburide 0-9 insulin Homo sapiens 35-42 3117833-0 1987 Acute effect of glyburide on insulin sensitivity in type I diabetic patients. Glyburide 16-25 insulin Homo sapiens 29-36 3117833-1 1987 Possible extrapancreatic effects of glyburide on insulin action were studied in six patients with insulin-dependent diabetes mellitus. Glyburide 36-45 insulin Homo sapiens 49-56 3117833-5 1987 During the glyburide infusion, the Biostator-determined insulin delivery rate was similar to that during the NaCl infusion for the first 6 h after the meal, but it decreased by 32% between the 6th and 12th hours after the meal. Glyburide 11-20 insulin Homo sapiens 56-63 3117833-6 1987 During the hyperinsulinemic clamp studies, glucose was delivered at a significantly higher rate when glyburide was infused; this was true for both rates of insulin infusion [5.6 +/- 1.9 (+/- SD) vs. 3.6 +/- 1.4 mg/kg.min and 12.1 +/- 2.4 vs. 9.1 +/- 2.1 mg/kg.min; P less than 0.05, glyburide vs. NaCl, respectively]. Glyburide 101-110 insulin Homo sapiens 16-23 3117833-8 1987 These results indicate that 1) glyburide has an acute effect on insulin action in insulin-dependent diabetic patients; and 2) this effect occurs at physiological as well as pharmacological insulin concentrations. Glyburide 31-40 insulin Homo sapiens 64-71 3117833-8 1987 These results indicate that 1) glyburide has an acute effect on insulin action in insulin-dependent diabetic patients; and 2) this effect occurs at physiological as well as pharmacological insulin concentrations. Glyburide 31-40 insulin Homo sapiens 82-89 3115853-4 1987 Serum glibenclamide levels rose to similar levels (160 ng/ml) with protocols A and C. Heart rate, blood pressure, and blood lactate levels increased immediately after onset of exercise and were comparable under conditions of protocols B and C. Serum insulin levels fell during protocol B from 6.1 +/- 0.6 to 4.0 +/- 0.3 microU/ml (P less than .001) but increased from 6.5 +/- 0.6 to 12.3 +/- 2.8 microU/ml during protocol A and from 6.6 +/- 0.6 to 12.7 +/- 4.3 microU/ml during protocol C, P less than .001. Glyburide 6-19 insulin Homo sapiens 250-257 3116364-11 1987 In conclusion, glyburide directly inhibited glycogenolysis, stimulated glycogen synthesis and glycogen synthase, and potentiated the action of insulin on glycogen synthesis at a postbinding site in cultured rat hepatocytes. Glyburide 15-24 insulin Homo sapiens 143-150 3106656-4 1987 Treatment with glyburide, 20 mg/d (plus insulin), compared with placebo (plus insulin) resulted in a significant reduction in mean basal glucose (232 +/- 12 vs 262 +/- 11 mg/dL [12.8 vs 14.4 mmol/L]) and hemoglobin A1C (10.2% +/- 0.5% vs 10.9% +/- 03%) concentrations. Glyburide 15-24 insulin Homo sapiens 40-47 3111514-11 1987 Plasma insulin concentrations were significantly elevated when H2-receptor antagonists and glibenclamide were administered concurrently. Glyburide 91-104 insulin Homo sapiens 7-14 3118579-0 1987 [Long-term effect of combination glibenclamide-insulin treatment in the secondary failure of sulfonylurea therapy--results of a one-year double blind study]. Glyburide 33-46 insulin Homo sapiens 47-54 3118579-2 1987 During a one-year follow-up period the patients on insulin plus glibenclamide required significantly lower exogenous insulin doses. Glyburide 64-77 insulin Homo sapiens 117-124 3118579-5 1987 Glibenclamide withdrawal after six and again after twelve months of the combined therapy provoked a deterioration of glycaemic control, as well as a lowering of the C-peptide concentrations. Glyburide 0-13 insulin Homo sapiens 165-174 2890501-0 1987 Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea. Glyburide 0-9 insulin Homo sapiens 20-27 2890501-12 1987 Glyburide increased basal and meal-but not glucagon-stimulated insulin and C-peptide levels, and also augmented the effect of meals on somatostatin release. Glyburide 0-9 insulin Homo sapiens 63-70 3034949-6 1987 In the absence of glucose, 1 microgram/mL glibenclamide increased insulin release. Glyburide 42-55 insulin Homo sapiens 66-73 3106656-4 1987 Treatment with glyburide, 20 mg/d (plus insulin), compared with placebo (plus insulin) resulted in a significant reduction in mean basal glucose (232 +/- 12 vs 262 +/- 11 mg/dL [12.8 vs 14.4 mmol/L]) and hemoglobin A1C (10.2% +/- 0.5% vs 10.9% +/- 03%) concentrations. Glyburide 15-24 insulin Homo sapiens 78-85 3106656-5 1987 Concomitant with this change, basal C-peptide and free insulin values increased with glyburide therapy, but this pharmacological agent did not alter the ability of the patient"s erythrocytes to bind insulin. Glyburide 85-94 insulin Homo sapiens 55-62 3106656-6 1987 We conclude that in type II diabetic subjects receiving more than 28 units of insulin per day, the addition of glyburide results in a marginal, but statistically significant improvement in basal glucose concentration, but not in glucose tolerance as assessed by integrated glucose concentration. Glyburide 111-120 insulin Homo sapiens 78-85 3104218-0 1987 Pharmacokinetics and pharmacological properties of two galenical preparations of glibenclamide, HB419 and HB420, in non insulin-dependent (type 2) diabetes. Glyburide 81-94 insulin Homo sapiens 120-127 3100365-8 1987 In contrast to the IDDM patients, the insulin-treated NIDDM subjects exhibited significant reductions in daily insulin requirement (72 +/- 6 vs. 58 +/- 9 U/day), mean 24-h plasma glucose concentration (153 +/- 10 vs. 131 +/- 5 mg/dl), glucosuria (14 +/- 5 vs. 4 +/- 1 g/day), and glycosylated hemoglobin (10.3 +/- 0.7 vs. 8.0 +/- 0.4%) after glyburide treatment (all P less than or equal to .05). Glyburide 342-351 insulin Homo sapiens 38-45 3097384-12 1986 The inhibition of insulin secretion (measured by C-peptide) caused by exogenous insulin administration is largely abolished by glibenclamide. Glyburide 127-140 insulin Homo sapiens 18-25 2878704-4 1986 The patient with impaired glucose tolerance due to insulin deficiency developed diabetes mellitus after four months" treatment; concomitant treatment with glibenclamide resulted in a decreased glucose concentration and increased insulin concentration. Glyburide 155-168 insulin Homo sapiens 51-58 3097384-12 1986 The inhibition of insulin secretion (measured by C-peptide) caused by exogenous insulin administration is largely abolished by glibenclamide. Glyburide 127-140 insulin Homo sapiens 80-87 3095909-0 1986 Potentiation by previous nutrients of glibenclamide-induced insulin release in man. Glyburide 38-51 insulin Homo sapiens 60-67 3095909-8 1986 We conclude that nutrients sensitize insulin-releasing cells to subsequent stimulation by glibenclamide, thereby aggravate a blood-glucose-lowering effect of the drug. Glyburide 90-103 insulin Homo sapiens 37-44 3098013-1 1986 The insulin binding of erythrocytes from: (i) fifteen age-matched normal subjects, (ii) ten untreated NIDDM patients and (iii) fifteen treated (glibenclamide + hypocaloric diet) NIDDM patients (all males) has been studied. Glyburide 144-157 insulin Homo sapiens 4-11 3092851-0 1986 Effect of oral verapamil on glibenclamide stimulated insulin secretion. Glyburide 28-41 insulin Homo sapiens 53-60 3092851-1 1986 In order to study the effect of the calcium antagonist, verapamil, on glibenclamide stimulated insulin release, nine healthy fasted male volunteers were given 5 mg oral glibenclamide with either 120 mg oral verapamil or placebo in a double-blind crossover manner 1 week apart. Glyburide 70-83 insulin Homo sapiens 95-102 3084315-4 1986 In the glibenclamide group, a significant increase in the number of hypoglycemic episodes was observed in spite of a 8 to 10% reduction in insulin requirements. Glyburide 7-20 insulin Homo sapiens 139-146 3085419-5 1986 Plasma glucose and insulin response to glibenclamide was also delayed in the delayed absorption group. Glyburide 39-52 insulin Homo sapiens 19-26 3935405-6 1985 The blood glucose level during insulin-glibenclamide therapy was 35-45 mg/dl below that during insulin-placebo treatment at all time points investigated. Glyburide 39-52 insulin Homo sapiens 31-38 3931459-4 1985 Glyburide therapy increased endogenous insulin secretion, increased adipocyte insulin binding after 18 but not three months of therapy, enhanced peripheral insulin action by acting primarily at a post-receptor site, and reduced basal hepatic glucose output. Glyburide 0-9 insulin Homo sapiens 39-46 3931459-4 1985 Glyburide therapy increased endogenous insulin secretion, increased adipocyte insulin binding after 18 but not three months of therapy, enhanced peripheral insulin action by acting primarily at a post-receptor site, and reduced basal hepatic glucose output. Glyburide 0-9 insulin Homo sapiens 78-85 3931466-3 1985 Glyburide lowered plasma glucose and raised plasma insulin concentrations in non-insulin-dependent diabetes mellitus. Glyburide 0-9 insulin Homo sapiens 51-58 3931466-4 1985 Patients with type IV hyperlipoproteinemia had higher fasting free insulin concentrations before and after therapy than patients without hyperlipoproteinemia and may have a slightly reduced hypoglycemic response to glyburide therapy. Glyburide 215-224 insulin Homo sapiens 67-74 3935120-1 1985 The effects of single oral dose of glibenclamide (Gilemid 5 mg) and chlorpropamide (250 mg) on serum insulin and glucose levels and electrolyte (sodium, potassium) balance were studied, in a cross-over double-blind manner, in 11 patients with non-insulin-dependent diabetes. Glyburide 35-48 insulin Homo sapiens 101-108 2951088-0 1985 The effect of glibenclamide administration on insulin sensitivity and insulin binding to monocytes in normal subjects. Glyburide 14-27 insulin Homo sapiens 46-53 2951088-0 1985 The effect of glibenclamide administration on insulin sensitivity and insulin binding to monocytes in normal subjects. Glyburide 14-27 insulin Homo sapiens 70-77 2951088-2 1985 Glibenclamide administration produced a 60% increase in maximal specific insulin binding to monocytes. Glyburide 0-13 insulin Homo sapiens 73-80 3923961-6 1985 The glyburide-induced fall in plasma glucose concentration was associated with improvements in both insulin secretion and insulin action, but only the enhanced insulin action correlated with the reduction in fasting and postprandial glucose levels. Glyburide 4-13 insulin Homo sapiens 100-107 3923833-4 1985 GL and CP produced essentially the same effects on serum levels of glucose, insulin, glucagon (IRG), growth hormone (GH), cholesterol, and triglyceride. Glyburide 0-2 insulin Homo sapiens 76-83 3923453-11 1985 Although glyburide is a potent stimulator of pancreatic insulin secretion after short-term administration, an additional mechanism of action during long-term administration is to decrease the resistance of muscle and liver to the action of insulin. Glyburide 9-18 insulin Homo sapiens 56-63 3919531-0 1985 Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone. Glyburide 65-78 insulin Homo sapiens 107-114 3931537-0 1985 Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients. Glyburide 27-40 insulin Homo sapiens 73-80 3931537-5 1985 The level of haemoglobin A, (HbA1) decreased significantly from 13.8 +/- 0.6% (mean +/- SE) to 12.4 +/- 0.6% during the insulin + glibenclamide period (p less than 0.01); in contrast, there was no change during the insulin + placebo period. Glyburide 130-143 insulin Homo sapiens 120-127 3931537-8 1985 The results suggest that glibenclamide can improve the glycaemic control in insulin-treated elderly diabetics by mechanisms which still are to be elucidated. Glyburide 25-38 insulin Homo sapiens 76-83 3934860-6 1985 These results suggest that a combination with glibenclamide leads to a decrease of insulin-requirement. Glyburide 46-59 insulin Homo sapiens 83-90 3924948-1 1985 The effect of glibenclamide treatment on insulin-mediated glucose disposal was studied in eight C-peptide-negative type I diabetic patients. Glyburide 14-27 insulin Homo sapiens 41-48 3924948-6 1985 The insulin-mediated glucose disposal rate was greater with glibenclamide during the first insulin infusion period (which generated plasma free insulin levels within the physiological range) 2.68 +/- 0.32 mg kg-1 min-1 with glibenclamide vs. 1.97 +/- 0.20 mg kg-1 min-1 without glibenclamide (P less than 0.005). Glyburide 60-73 insulin Homo sapiens 4-11 3924948-6 1985 The insulin-mediated glucose disposal rate was greater with glibenclamide during the first insulin infusion period (which generated plasma free insulin levels within the physiological range) 2.68 +/- 0.32 mg kg-1 min-1 with glibenclamide vs. 1.97 +/- 0.20 mg kg-1 min-1 without glibenclamide (P less than 0.005). Glyburide 60-73 insulin Homo sapiens 91-98 3924948-6 1985 The insulin-mediated glucose disposal rate was greater with glibenclamide during the first insulin infusion period (which generated plasma free insulin levels within the physiological range) 2.68 +/- 0.32 mg kg-1 min-1 with glibenclamide vs. 1.97 +/- 0.20 mg kg-1 min-1 without glibenclamide (P less than 0.005). Glyburide 60-73 insulin Homo sapiens 91-98 3924948-6 1985 The insulin-mediated glucose disposal rate was greater with glibenclamide during the first insulin infusion period (which generated plasma free insulin levels within the physiological range) 2.68 +/- 0.32 mg kg-1 min-1 with glibenclamide vs. 1.97 +/- 0.20 mg kg-1 min-1 without glibenclamide (P less than 0.005). Glyburide 224-237 insulin Homo sapiens 4-11 3924948-6 1985 The insulin-mediated glucose disposal rate was greater with glibenclamide during the first insulin infusion period (which generated plasma free insulin levels within the physiological range) 2.68 +/- 0.32 mg kg-1 min-1 with glibenclamide vs. 1.97 +/- 0.20 mg kg-1 min-1 without glibenclamide (P less than 0.005). Glyburide 224-237 insulin Homo sapiens 4-11 3924948-8 1985 These results provide evidence for an extrapancreatic effect of glibenclamide at low insulin concentrations during euglycemic clamping in patients with insulin-dependent diabetes mellitus. Glyburide 64-77 insulin Homo sapiens 85-92 3935120-2 1985 Both drugs increased serum insulin for more than 8 h but less than 24 h. The effect of glibenclamide was slightly stronger than that of chlorpropamide. Glyburide 87-100 insulin Homo sapiens 27-34 3933984-7 1985 Insulin sensitivity was increased by glibenclamide but not by glipizide. Glyburide 37-50 insulin Homo sapiens 0-7 3933984-10 1985 Only glibenclamide improved insulin sensitivity and was slightly more active than glipizide on fasting blood glucose levels. Glyburide 5-18 insulin Homo sapiens 28-35 6432610-9 1984 After glyburide, insulin-mediated glucose metabolism increased by 26% to 3.67 mg/kg X min (P less than 0.01). Glyburide 6-15 insulin Homo sapiens 17-24 6435371-0 1984 Improved diabetic control in insulin-dependent diabetics treated with insulin and glibenclamide. Glyburide 82-95 insulin Homo sapiens 29-36 6435371-5 1984 Combined insulin and glibenclamide treatment may produce a useful improvement of diabetic control in insulin-dependent diabetics who still secrete some endogenous insulin, although further studies are required. Glyburide 21-34 insulin Homo sapiens 101-108 6432273-0 1984 [Effect of glibenclamide therapy on the plasma insulin level in non-insulin-dependent diabetes]. Glyburide 11-24 insulin Homo sapiens 47-54 6428843-3 1984 Insulin receptors of peripheral monocytes were initially normal in both number and affinity in this group of insulin-dependent diabetic patients, but, after 6 mo of glyburide therapy, binding to insulin receptors declined at the lower insulin concentration range without falling out of the normal range. Glyburide 165-174 insulin Homo sapiens 0-7 6428843-3 1984 Insulin receptors of peripheral monocytes were initially normal in both number and affinity in this group of insulin-dependent diabetic patients, but, after 6 mo of glyburide therapy, binding to insulin receptors declined at the lower insulin concentration range without falling out of the normal range. Glyburide 165-174 insulin Homo sapiens 195-202 6429023-0 1984 Hyperglycaemic clamp and insulin binding to isolated monocytes before and after glibenclamide treatment of mild type II diabetics. Glyburide 80-93 insulin Homo sapiens 25-32 6376033-7 1984 Thus, after 3 mo of glyburide treatment, glycemic control is markedly improved and this is accompanied by an increase in insulin secretion, no change in cellular insulin receptors, decreased hepatic glucose production rates, and an increase in overall insulin-mediated glucose disposal. Glyburide 20-29 insulin Homo sapiens 121-128 6376033-8 1984 After 18 mo of glyburide treatment, an increase in insulin secretion can no longer be demonstrated, whereas insulin binding to receptors is now significantly increased. Glyburide 15-24 insulin Homo sapiens 51-58 6439409-8 1984 While glyburide produces an insulin release response to glucose that parallels a normal physiological response, it appears to also decrease resistance to insulin and sensitize the receptors while utilizing the patient"s available endogenous insulin. Glyburide 6-15 insulin Homo sapiens 28-35 6424413-4 1984 The results indicate that the glibenclamide-induced insulin release can be resolved in a "high-affinity" component, which correlates with increased osmotic resistance in the beta-cells and a "low-affinity" component not associated with increased osmotic resistance. Glyburide 30-43 insulin Homo sapiens 52-59 6439409-8 1984 While glyburide produces an insulin release response to glucose that parallels a normal physiological response, it appears to also decrease resistance to insulin and sensitize the receptors while utilizing the patient"s available endogenous insulin. Glyburide 6-15 insulin Homo sapiens 154-161 6439409-8 1984 While glyburide produces an insulin release response to glucose that parallels a normal physiological response, it appears to also decrease resistance to insulin and sensitize the receptors while utilizing the patient"s available endogenous insulin. Glyburide 6-15 insulin Homo sapiens 154-161 6437842-3 1984 The combined administration of glibenclamide and acarbose resulted in a modest improvement in the blood glucose profile after breakfast and lunch, together with a significant diminution in plasma insulin. Glyburide 31-44 insulin Homo sapiens 196-203 6415086-6 1983 The in vitro studies with monocytes revealed a dose-related insulin receptor stimulatory effect of glibenclamide (P less than 0.05), with a maximal effect of 20% above basal level. Glyburide 99-112 insulin Homo sapiens 60-67 6415086-7 1983 These data indicate that glibenclamide increases the insulin-binding ability of monocytes but not of erythrocytes. Glyburide 25-38 insulin Homo sapiens 53-60 6415086-0 1983 The effect of glibenclamide on insulin receptors in normal man: comparative studies of insulin binding to monocytes and erythrocytes. Glyburide 14-27 insulin Homo sapiens 31-38 6800910-16 1982 These finding suggest that the hypoglycemic effect of glibenclamide treatment in the short term is mainly, if not entirely, due to augmented endogenous insulin secretion. Glyburide 54-67 insulin Homo sapiens 152-159 6415086-3 1983 Oral administration of glibenclamide in dose of 2.5 mg/day increased insulin binding to monocytes by 70% (P less than 0.001), in spite of increased postprandial serum insulin levels. Glyburide 23-36 insulin Homo sapiens 69-76 6415086-3 1983 Oral administration of glibenclamide in dose of 2.5 mg/day increased insulin binding to monocytes by 70% (P less than 0.001), in spite of increased postprandial serum insulin levels. Glyburide 23-36 insulin Homo sapiens 167-174 6136627-3 1983 Basal levels of growth hormone and of pancreatic and gastric hormones were reduced and the response of growth hormone, insulin and C-peptide to stimuli such as arginine, glucose, glibenclamide and calcium was virtually abolished. Glyburide 179-192 insulin Homo sapiens 119-126 6413265-3 1983 Glibenclamide plus diet succeeded in improving glucose tolerance only in low insulin responders whereas glucose tolerance remained unchanged in normal insulin responders. Glyburide 0-13 insulin Homo sapiens 77-84 6413265-4 1983 There was a significant decrease in fasting and glucose-stimulated insulin levels after two years of glibenclamide treatment in both the normal and low insulin-responders. Glyburide 101-114 insulin Homo sapiens 67-74 6413265-4 1983 There was a significant decrease in fasting and glucose-stimulated insulin levels after two years of glibenclamide treatment in both the normal and low insulin-responders. Glyburide 101-114 insulin Homo sapiens 152-159 6401923-5 1983 Therapy with the second-generation sulfonylurea compound glyburide enhances overall insulin responsiveness without altering insulin binding. Glyburide 57-66 insulin Homo sapiens 84-91 6401923-6 1983 Prevailing insulin levels are increased markedly during glyburide therapy but do not correlate with the clinical response, which suggests that the improvement in target tissue insulin action is the critical determinant in terms of the clinical response to the drug. Glyburide 56-65 insulin Homo sapiens 11-18 6401923-6 1983 Prevailing insulin levels are increased markedly during glyburide therapy but do not correlate with the clinical response, which suggests that the improvement in target tissue insulin action is the critical determinant in terms of the clinical response to the drug. Glyburide 56-65 insulin Homo sapiens 176-183 6401923-7 1983 In vitro studies utilizing cultured human fibroblasts indicate that glyburide increases the number of cell-surface insulin receptors and opposes insulin-mediated down-regulation. Glyburide 68-77 insulin Homo sapiens 115-122 6401923-7 1983 In vitro studies utilizing cultured human fibroblasts indicate that glyburide increases the number of cell-surface insulin receptors and opposes insulin-mediated down-regulation. Glyburide 68-77 insulin Homo sapiens 145-152 6805141-5 1981 In general the improvement of the glucose tolerance was not associated with an increased secretion of insulin, so that an extrapancreatic effect of glibenclamide (improvement of the peripheral insulin sensitivity?) Glyburide 148-161 insulin Homo sapiens 193-200 7029541-2 1981 Identification of the Golgi apparatus by immunofluorescence required the prior degranulation of B cells with glibenclamide to reduce the insulin immunostaining due to secretory granules. Glyburide 109-122 insulin Homo sapiens 137-144 7029541-4 1981 With the electron microscope, the insulin immunoreactive sites revealed by the protein A/gold technique were localized in the cisternae and vesicles of the Golgi apparatus of glibenclamide-treated and control B cells and over maturing and mature secretory granules. Glyburide 175-188 insulin Homo sapiens 34-41 6772676-1 1980 We have studied the effects of the oral sulfonylurea agent glyburide to modulate insulin receptors on nontransformed human fibroblasts in tissue culture. Glyburide 59-68 insulin Homo sapiens 81-88 6777211-0 1980 The effect of glibenclamide on the glucose and insulin profile in maturity onset diabetics following both acute and long term treatment. Glyburide 14-27 insulin Homo sapiens 47-54 6776759-0 1980 Stimulation of residual insulin secretion by glibenclamide in insulin dependent diabetics. Glyburide 45-58 insulin Homo sapiens 24-31 6776759-3 1980 It is suggested that glibenclamide might be a useful adjunct to insulin therapy in insulin-requiring diabetics who still secrete C-peptide. Glyburide 21-34 insulin Homo sapiens 83-90 6772676-4 1980 When the process of insulin-induced receptor loss (or down regulation) was studied in the presence of glyburide, the drug exerted a marked inhibitory effect on this regulatory process. Glyburide 102-111 insulin Homo sapiens 20-27 6772676-5 1980 Thus, glyburide inhibited insulin-induced receptor loss in a dose-dependent fashion, and the maximally effective drug concentration (1 microgram/ml) inhibited 34% of the receptor loss. Glyburide 6-15 insulin Homo sapiens 26-33 6776763-0 1980 Diurnal pattern of plasma insulin and blood glucose during glibenclamide and glipizide therapy in elderly diabetics. Glyburide 59-72 insulin Homo sapiens 26-33 6778077-0 1980 Effects of glucagon and pentagastrin on glibenclamide-induced insulin release. Glyburide 40-53 insulin Homo sapiens 62-69 6778077-6 1980 Glucagon in contrast to pentagastrin thus positively modulates the insulin secretory pathway stimulated by the sulphonylurea drug glibenclamide. Glyburide 130-143 insulin Homo sapiens 67-74 6776763-1 1980 The effect of a single and a split dose of glibenclamide and glipizide on the diurnal levels of blood glucose and plasma insulin were compared in 15 insulin-independent diabetics. Glyburide 43-56 insulin Homo sapiens 121-128 111449-1 1979 The effect of two second generation sulphonylureas, gliquidone and glibenclamide, on insulin secretion has been studied in the basal state and in combination with glucose infusions in normal controls, patients with mild maturity-onset diabetes, and subjects with normal glucose tolerance but low insulin response. Glyburide 67-80 insulin Homo sapiens 85-92 115730-0 1979 The effect of glibenclamide treatment on the insulin and glucagon responses to oral glucose and galactose in maturity onset diabetics. Glyburide 14-27 insulin Homo sapiens 45-52 115730-1 1979 Glibenclamide has been shown to stimulate an insulin releasing factor in the duodenum. Glyburide 0-13 insulin Homo sapiens 45-52 6778079-4 1980 Glipizide and glibenclamide were more potent inducers of insulin release and blood glucose reduction than tolbutamide and chlorpropamide. Glyburide 14-27 insulin Homo sapiens 57-64 111449-2 1979 When injected intravenously, gliquidone caused rapid elevation of plasma insulin, peaking at 5 min in all groups, while glibenclamide induced a slow rise in insulin. Glyburide 120-133 insulin Homo sapiens 157-164 111449-4 1979 In all groups, 25 micrograms/kg glibenclamide and 200 micrograms/kg gliquidone were equipotent in generating an insulin response at the basal state. Glyburide 32-45 insulin Homo sapiens 112-119 111449-7 1979 Addition of sulphonylurea induced a left shift in the dose-response relationships in controls and low insulin responders; under these conditions the effect of glibenclamide was more pronounced than that of gliquidone. Glyburide 159-172 insulin Homo sapiens 102-109 106617-0 1979 Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide. Glyburide 103-116 insulin Homo sapiens 10-17 106617-0 1979 Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide. Glyburide 103-116 insulin Homo sapiens 43-50 106617-1 1979 The aim of the present study was to examine the effect of glibenclamide on the insulin receptors, the insulin sensitivity and the insulin secretion in obese non-ketotic diabetics. Glyburide 58-71 insulin Homo sapiens 79-86 106617-6 1979 In the group treated with glibenclamide and diet the insulin secretory pattern was unchanged, too (p greater than 0.1). Glyburide 26-39 insulin Homo sapiens 53-60 106617-10 1979 After 1 year we found a significantly (P less than 0.005) higher cellular insulin binding in the glibenclamide treated patients compared to the patients who got diet alone. Glyburide 97-110 insulin Homo sapiens 74-81 106617-11 1979 We conclude that 1) the augmentation of the insulin sensitivity is of great importance for the normalization of the diabetic state in obese, 2) the increase in insulin binding may be of importance for the increase in insulin sensitivity, 3) glibenclamide appears to enhance the insulin sensitivity through an increase in the number of insulin receptors. Glyburide 241-254 insulin Homo sapiens 44-51 106617-11 1979 We conclude that 1) the augmentation of the insulin sensitivity is of great importance for the normalization of the diabetic state in obese, 2) the increase in insulin binding may be of importance for the increase in insulin sensitivity, 3) glibenclamide appears to enhance the insulin sensitivity through an increase in the number of insulin receptors. Glyburide 241-254 insulin Homo sapiens 160-167 106617-11 1979 We conclude that 1) the augmentation of the insulin sensitivity is of great importance for the normalization of the diabetic state in obese, 2) the increase in insulin binding may be of importance for the increase in insulin sensitivity, 3) glibenclamide appears to enhance the insulin sensitivity through an increase in the number of insulin receptors. Glyburide 241-254 insulin Homo sapiens 160-167 106617-11 1979 We conclude that 1) the augmentation of the insulin sensitivity is of great importance for the normalization of the diabetic state in obese, 2) the increase in insulin binding may be of importance for the increase in insulin sensitivity, 3) glibenclamide appears to enhance the insulin sensitivity through an increase in the number of insulin receptors. Glyburide 241-254 insulin Homo sapiens 160-167 106617-11 1979 We conclude that 1) the augmentation of the insulin sensitivity is of great importance for the normalization of the diabetic state in obese, 2) the increase in insulin binding may be of importance for the increase in insulin sensitivity, 3) glibenclamide appears to enhance the insulin sensitivity through an increase in the number of insulin receptors. Glyburide 241-254 insulin Homo sapiens 160-167 101402-3 1978 There was no significant difference between serum insulin concentrations on the two doses, however, serum insulin/blood glucose ratio was higher during the larger dose of glibenclamide. Glyburide 171-184 insulin Homo sapiens 106-113 415745-0 1978 [Insulin and pro-insulin secretion following intravenous administration of tolbutamide, glisoxepide and glibenclamide]. Glyburide 104-117 insulin Homo sapiens 1-8 415745-4 1978 The maximum level of insulin follows the injection of tolbutamide with a value of 70.5 micronU/ml after 2 min, of glisoxepide after 5 min (67.0 micronU/ml) and of glibenclamide after 20 min (32.3 micronU/ml). Glyburide 163-176 insulin Homo sapiens 21-28 413023-1 1978 Eleven insulin-dependent ketosis-prone diabetics were given glibenclamide (5 mg/day) in addition to their usual insulin treatment for a period of 1 or 6 mo. Glyburide 60-73 insulin Homo sapiens 7-14 411723-1 1977 The blood glucose and plasma insulin response to the two hypoglycaemic agents, chlorpropamide (Diabenese) and glibenclamide (Daonil) was determined in normal subjects under strict metabolic control in a double blind study. Glyburide 110-123 insulin Homo sapiens 29-36 411723-5 1977 Chlorpropamide was capable of lowering blood glucose without raising plasma insulin levels, whereas glibenclamide produced a prolonged and marked increase in plasma insulin levels only to be associated with a short-lived hypoglycaemic response. Glyburide 100-113 insulin Homo sapiens 165-172 411723-6 1977 The latter suggested that a degree of insulin resistance had been produced secondary to the early profound lowering of the blood glucose following glibenclamide. Glyburide 147-160 insulin Homo sapiens 38-45 403065-0 1977 [Attempted suicide using glibenclamide:course of glucose, insulin, glibenclamide and C-peptide blood levels]. Glyburide 25-38 insulin Homo sapiens 85-94 410692-5 1977 It is concluded that calcium may temporarily improve carbohydrate tolerance in diabetic patients by potentiating the glibenclamide-stimulated insulin secretion. Glyburide 117-130 insulin Homo sapiens 142-149 410692-0 1977 Potentiation of glibenclamide-induced insulin release by calcium infusion. Glyburide 16-29 insulin Homo sapiens 38-45 410692-1 1977 The effect of calcium on glibenclamide-induced insulin release was studied in 14 diabetic patients. Glyburide 25-38 insulin Homo sapiens 47-54 811925-1 1975 The effects of tolbutamide, glibenclamide, arginine and arginine in combination with glibenclamide upon insulin, glucagon and glucose serum levels have been studied in healthy young men. Glyburide 85-98 insulin Homo sapiens 104-111 404205-6 1977 Serum insulin concentration was higher on glibenclamide than with either biguanide. Glyburide 42-55 insulin Homo sapiens 6-13 12072-1 1976 Sustained, 60-minute perfusion of glibenclamide (0.5, 1.5 and 10 mug/ml) elicits a one-phase insulin release profile, formed by a rapid secretion peak followed by a second peak with lower insulin levels than the former. Glyburide 34-47 insulin Homo sapiens 93-100 12072-1 1976 Sustained, 60-minute perfusion of glibenclamide (0.5, 1.5 and 10 mug/ml) elicits a one-phase insulin release profile, formed by a rapid secretion peak followed by a second peak with lower insulin levels than the former. Glyburide 34-47 insulin Homo sapiens 188-195 12072-7 1976 Both theophylline and phentolamine modify and increase the glibenclamide-induced insulin release pattern. Glyburide 59-72 insulin Homo sapiens 81-88 12072-8 1976 Propranolol and imidazole inhibit glibenclamide-induced insulin release. Glyburide 34-47 insulin Homo sapiens 56-63 12072-12 1976 Glibenclamide and glucose induce secretion of insulin originating in the same compartment. Glyburide 0-13 insulin Homo sapiens 46-53 814956-4 1976 Treatment with glibenclamide increased insulin secretion but phenformin had no significant effect. Glyburide 15-28 insulin Homo sapiens 39-46 829387-0 1976 [Blood sugar and serum insulin levels with reference to the glibenclamide concentration in suicidal glibenclamide poisoning. Glyburide 60-73 insulin Homo sapiens 23-30 829387-0 1976 [Blood sugar and serum insulin levels with reference to the glibenclamide concentration in suicidal glibenclamide poisoning. Glyburide 100-113 insulin Homo sapiens 23-30 804684-0 1975 [Daily curves of blood sugar and serum insulin after treatment with various combinations of glibenclamide and phenformin]. Glyburide 92-105 insulin Homo sapiens 39-46 805520-2 1975 Diabetics controlled on diet therapy showed no change in disaccharidase activity while two diabetics controlled on insulin or insulin-producing drug, glibenclamide, showed a fall in disaccharidase values toward normal. Glyburide 150-163 insulin Homo sapiens 126-133 4201174-1 1973 Inhibitory effects of a membrane probe on the islet uptake and insulin-releasing action of glibenclamide. Glyburide 91-104 insulin Homo sapiens 63-70 4198966-2 1972 Increase of the effect of insulin due to tolbutamide, glibornuride, and glibenclamide in vitro]. Glyburide 72-85 insulin Homo sapiens 26-33 4353086-10 1973 The sulphonylureas, tolbutamide and glibenclamide, agents that increase insulin release, also increased the protein kinase activity; however, leucine, arginine and xylitol, which also stimulate insulin release, were without effect on the kinase activity. Glyburide 36-49 insulin Homo sapiens 72-79 4197367-0 1973 [Plasma insulin and glucose levels in diabetics treated with glibenclamide and chlorporpamide]. Glyburide 61-74 insulin Homo sapiens 8-15 5434298-0 1970 Effects of glycodiazin and glybenclamide upon insulin secretion in vitro. Glyburide 27-40 insulin Homo sapiens 46-53 4622788-0 1972 Profile of insulin release due to intrapancreatic glyburide infusion. Glyburide 50-59 insulin Homo sapiens 11-18 5005528-0 1971 [Is the increase of hypoglycemic reactions during glibenclamide therapy due to a substance-specific stronger stimulation of the insulin secretion? Glyburide 50-63 insulin Homo sapiens 128-135 5005530-0 1971 [Behavior of serum insulin in the double intravenous glucose tolerance test in diabetics before and during glibenclamide therapy]. Glyburide 107-120 insulin Homo sapiens 19-26 5526611-1 1970 A clinical and metabolic study of 32 patients treated with glibenclamide for a period of about one year confirmed that the drug is a potent stimulator of insulin release in maturity onset diabetes, and glibenclamide continued to have this action after a period of eight months. Glyburide 59-72 insulin Homo sapiens 154-161 5440469-0 1970 [Blood sugar and plasma insulin levels in children following the oral administration of glybenclamide (HB 419)]. Glyburide 88-101 insulin Homo sapiens 24-31 5533294-0 1970 Plasma insulin and metabolic study on diabetes treated with glibenclamide. Glyburide 60-73 insulin Homo sapiens 7-14 4107054-0 1970 [In-vitro changes of the serum binding capacity for 131 I-insulin under tolbutamide and glybenclamide in normal persons, in juvenile and senile diabetes, as well as in insulin resistance]. Glyburide 89-102 insulin Homo sapiens 59-66 32442232-16 2020 Glyburide-exposed neonates were heavier at birth (58.20 g, 95% confidence interval [CI] 10.10-106.31, p = 0.02) with increased risk of macrosomia (odds ratio [OR] 1.38, 95% CI 1.01-1.89, p = 0.04) versus neonates of insulin-treated mothers. Glyburide 0-9 insulin Homo sapiens 216-223 32274916-10 2020 EVIDENCE SYNTHESIS: The discovery of the pathogenesis of most forms of congenital diabetes has made it possible to adapt the therapy to the diagnosis and in the forms of alteration of the potassium channels of the pancreatic Beta cels the switch from insulin to Glibenclamide per os has greatly improved the quality of life. Glyburide 262-275 insulin Homo sapiens 251-258 32442232-19 2020 Glyburide-exposed neonates had a nonsignificant increase in total fat mass (103.2 g, 95% CI -3.91 to 210.31, p = 0.06) and increased abdominal (0.90 cm, 95% CI 0.03-1.77, p = 0.04) and chest circumferences (0.80 cm, 95% CI 0.07-1.53, p = 0.03) versus insulin-exposed neonates. Glyburide 0-9 insulin Homo sapiens 251-258 31733313-10 2020 In contrast, GBC treatment improved memory impairment, increased insulin, and reduced glucose and hippocampal inflammation in rats with T2D and sporadic AD. Glyburide 13-16 insulin Homo sapiens 65-72 30172767-12 2019 CONCLUSIONS: A majority of hypoglycemic events occurred in elderly patients with type 2 DM, with a high prevalence of associated comorbidities and treated with insulin and sulfonylureas, particularly glibenclamide. Glyburide 200-213 insulin Homo sapiens 160-167 31989292-6 2020 The pooled estimate showed that glyburide significantly decreased the need for cesarean section (OR = 0.87, 95% CI [0.82, 0.92], p < 0.0001), fasting blood glucose (MD - 5.63 mg/dL, 95% CI [- 10.97, - 0.28], p = 0.04), and Apgar score at 5 min (MD - 0.30, 95% CI [- 0.36, - 0.23], p < 0.001) than insulin. Glyburide 32-41 insulin Homo sapiens 303-310 31989292-7 2020 However, glyburide significantly increased the risk of neonatal hypoglycemia (OR = 1.42, 95% CI [1.03, 1.95], p = 0.03) and neonatal intensive care unit admission duration (NICU) (MD 4.26 days, 95% CI [2.65, 5.86], p < 0.01) compared to insulin. Glyburide 9-18 insulin Homo sapiens 240-247 31479156-10 2019 The macrosomia rate was higher in the glibenclamide-exposed group than the insulin-alone group (12.2% vs 0%, P=0.025). Glyburide 38-51 insulin Homo sapiens 75-82 31292311-0 2019 The differential influence of glimepiride and glibenclamide on insulin resistance and adiponectin levels in patients with type 2 diabetes. Glyburide 46-59 insulin Homo sapiens 63-70 31511772-0 2019 Glibenclamide-Induced Autophagy Inhibits Its Insulin Secretion-Improving Function in beta Cells. Glyburide 0-13 insulin Homo sapiens 45-52 31511772-6 2019 Herein, we showed that glibenclamide promoted insulin release and further activated autophagy through the adenosine 5"-monophosphate (AMP) activated protein kinase (AMPK) pathway in MIN-6 cells. Glyburide 23-36 insulin Homo sapiens 46-53 29305569-0 2018 Emergence of insulin resistance following empirical glibenclamide therapy: a case report of neonatal diabetes with a recessive INS gene mutation. Glyburide 52-65 insulin Homo sapiens 13-20 29679622-3 2018 We have more information regarding treatment of women with gestational diabetes mellitus where glyburide can induce a picture of fetal hyperinsulinism (higher birthweight and more neonatal hypoglycemia) whereas metformin requires supplemental insulin in a larger proportion of women but achieves satisfactory perinatal outcomes with the exception of preterm birth. Glyburide 95-104 insulin Homo sapiens 140-147 30094785-9 2018 The gene analysis revealed a de novo mutation (c.602G > A (p.R201H)) of the KCNJ11 gene, and oral glibenclamide successfully replaced insulin treatment in the patient. Glyburide 101-114 insulin Homo sapiens 137-144 26831749-9 2016 Moreover, as showed in the first two case-reports, when the treatment was switched from insulin to glibenclamide, according to identification of Kir 6.2 mutation and diagnosis of NPDM, the CSII therapy demonstrated to be helpful in allowing gradual insulin suspension and progressive introduction of sulfonylurea. Glyburide 99-112 insulin Homo sapiens 249-256 28938877-12 2017 The combination of metformin and glibenclamide should be reserved for women with GDM with true needle phobia or inability to use insulin therapy. Glyburide 33-46 insulin Homo sapiens 129-136 28930827-14 2017 Ranking results showed that glyburide might be the optimum treatment regarding average glucose control, and metformin is the fastest in glucose control for GDM patients; glyburide have the highest incidence of macrosomia, preeclampsia, hyperbilirubinemia, neonatal hypoglycemia, shortest gestational age at delivery, and lowest mean birth weight; metformin (plus insulin when required) have the lowest incidence of macrosomia, PIH, LGA, RDS, low gestational age at delivery, and low birth weight. Glyburide 170-179 insulin Homo sapiens 363-370 28556992-7 2017 If the fetus inherits a KATP neonatal diabetes mutation from their mother they have greatly reduced insulin secretion in utero that reduces fetal growth by ~900 g. Treating the mother with glibenclamide in the third trimester treats the affected fetus in utero, normalising fetal growth, but is not desirable, especially in the high doses used in this condition, if the fetus is unaffected. Glyburide 189-202 insulin Homo sapiens 100-107 28077460-11 2017 In the glyburide group, nine (17%) patients were eventually treated with insulin compared with two (4%) in the metformin group (P = 0.03). Glyburide 7-16 insulin Homo sapiens 73-80 27316908-0 2017 Mechanism of Action of Novel Glibenclamide Derivatives on Potassium and Calcium Channels for Insulin Secretion. Glyburide 29-42 insulin Homo sapiens 93-100 26796130-3 2016 Glyburide failure was defined as reaching glyburide 20 mg day(-1) and receiving insulin. Glyburide 0-9 insulin Homo sapiens 80-87 27163280-4 2016 Insulin has traditionally been the treatment of choice but since 2007, glyburide, a second generation sulfonylurea has become the most prescribed medication for GDM. Glyburide 71-80 insulin Homo sapiens 0-7 26796130-4 2016 Glyburide success was defined as any glyburide dose without insulin and >70% of visits with glycemic control. Glyburide 0-9 insulin Homo sapiens 60-67 26132275-5 2015 Dose-dependent decreases in blood glucose and increases in plasma insulin concentrations were seen with the combination of MK-467 and glibenclamide; the combinations were much more potent than glibenclamide or MK-467 alone. Glyburide 134-147 insulin Homo sapiens 66-73 26609764-6 2016 We found that few studies reported information on beta-cell function effects in GDM, despite some agents, such as glyburide, are well known insulin secretagogues. Glyburide 114-123 insulin Homo sapiens 140-147 26331221-9 2015 Interestingly, C-peptide levels raise during glibenclamide administration support some degree of improvement in insulin secretory capacity induced by the treatment. Glyburide 45-58 insulin Homo sapiens 112-119 25765720-13 2015 However, during moderate hyperinsulinemic hypoglycemia (2.9mmol/L) glyburide resulted in increased C-peptide and insulin, but blunted glucagon, sympathetic nervous system and EGP responses. Glyburide 67-76 insulin Homo sapiens 30-37 26548081-4 2015 In the present study, we explored the binding interactions of antidiabetic drugs i.e., sulfonylurea drugs (glimepiride, glipizide, glyburide) and rapid acting insulin secretagogues viz., nateglinide, repaglinide and rosiglitazone; and Pgp inhibitors i.e., Generation I (verapamil and tamoxifen), III (tetradrine and tariquidar), and natural inhibitors (fumagillin and piperine) in mouse Pgp model. Glyburide 131-140 insulin Homo sapiens 159-166 26438710-4 2015 However, contemporary administration of insulin with an insulin secretagogue (glyburide), and of additional drugs, can make the diagnostic pathway problematic. Glyburide 78-87 insulin Homo sapiens 40-47 26438710-4 2015 However, contemporary administration of insulin with an insulin secretagogue (glyburide), and of additional drugs, can make the diagnostic pathway problematic. Glyburide 78-87 insulin Homo sapiens 56-63 25580176-13 2014 CONCLUSION: Glyburide and metformin appear to be safe and effective to manage blood glucose in patients with gestational diabetes who prefer to not utilize insulin or who cannot afford insulin therapy. Glyburide 12-21 insulin Homo sapiens 185-192 25315294-1 2014 Oral hypoglycemic agents such as glyburide (second-generation sulfonylurea) and metformin (biguanide) are attractive alternatives to insulin due to lower cost, ease of administration, and better patient adherence. Glyburide 33-42 insulin Homo sapiens 133-140 25297572-0 2015 The effect of glibenclamide on insulin secretion at normal glucose concentrations. Glyburide 14-27 insulin Homo sapiens 31-38 25297572-9 2015 CONCLUSIONS/INTERPRETATION: At low-normal glucose, glibenclamide exerted a disproportionate effect on insulin secretion. Glyburide 51-64 insulin Homo sapiens 102-109 25665835-12 2015 However, glibenclamide treatment of the patient on a reduced dose of insulin did not reduce HbA1c levels, and C-peptide increased only very slightly. Glyburide 9-22 insulin Homo sapiens 69-76 23921548-3 2013 (2) Interestingly, therapies to improve glucose homeostasis in diabetic patients usually involve the use of glibenclamide, an oral hypoglycemic drug that blocks ATP-sensitive K(+) channels (KATP), (3)(,) (4) forcing beta cells to release more insulin to overcome peripheral insulin resistance. Glyburide 108-121 insulin Homo sapiens 243-250 24150606-6 2014 Here, we show that transient overexpression of human OATP1B3 in a murine beta-cell line (MIN6)-which exhibits glucose and glibenclamide-sensitive insulin secretion-significantly enhances the insulinotropic effect of glibenclamide without affecting glucose-stimulated insulin secretion. Glyburide 122-135 insulin Homo sapiens 146-153 24150606-6 2014 Here, we show that transient overexpression of human OATP1B3 in a murine beta-cell line (MIN6)-which exhibits glucose and glibenclamide-sensitive insulin secretion-significantly enhances the insulinotropic effect of glibenclamide without affecting glucose-stimulated insulin secretion. Glyburide 216-229 insulin Homo sapiens 191-198 24767162-6 2014 The coverage rates of acarbose (48.9%), metformin(40.7%) and human insulin (31.1%) were higher than those of glimepiride (9.4%), glipizide (3.0%), glibenclamide (0.6%) and animal insulin (0.2%). Glyburide 147-160 insulin Homo sapiens 67-74 24767162-9 2014 The coverage rates of acarbose (49.7%), metformin (36.3%) and insulin (30.4%) were still higher than those of glimepiride (6.3%), glipizide (2.2%) , glibenclamide (0.4%) and animal insulin(0.0%). Glyburide 149-162 insulin Homo sapiens 62-69 24741335-1 2014 BACKGROUND: The purpose of this study was to investigate the effect of glibenclamide dose escalation on blood glucose and insulin in patients with poorly controlled type 2 diabetes. Glyburide 71-84 insulin Homo sapiens 122-129 23921548-3 2013 (2) Interestingly, therapies to improve glucose homeostasis in diabetic patients usually involve the use of glibenclamide, an oral hypoglycemic drug that blocks ATP-sensitive K(+) channels (KATP), (3)(,) (4) forcing beta cells to release more insulin to overcome peripheral insulin resistance. Glyburide 108-121 insulin Homo sapiens 274-281 24275850-1 2013 First introduced into clinical practice in 1969, glibenclamide (US adopted name, glyburide) is known best for its use in the treatment of diabetes mellitus type 2, where it is used to promote the release of insulin by blocking pancreatic KATP [sulfonylurea receptor 1 (Sur1)-Kir6.2] channels. Glyburide 49-62 insulin Homo sapiens 207-214 24275850-1 2013 First introduced into clinical practice in 1969, glibenclamide (US adopted name, glyburide) is known best for its use in the treatment of diabetes mellitus type 2, where it is used to promote the release of insulin by blocking pancreatic KATP [sulfonylurea receptor 1 (Sur1)-Kir6.2] channels. Glyburide 81-90 insulin Homo sapiens 207-214 23427864-6 2013 Fasting plasma insulin level and the homeostasis model assessment insulin resistance index were significantly increased by triple therapy with glibenclamide and decreased by the one with sitagliptin. Glyburide 143-156 insulin Homo sapiens 15-22 23413771-4 2013 Fasting plasma insulin and homeostasis model assessment of insulin resistance were significantly increased by triple therapy with glibenclamide and decreased by that with sitagliptin. Glyburide 130-143 insulin Homo sapiens 15-22 23413771-4 2013 Fasting plasma insulin and homeostasis model assessment of insulin resistance were significantly increased by triple therapy with glibenclamide and decreased by that with sitagliptin. Glyburide 130-143 insulin Homo sapiens 59-66 23427864-6 2013 Fasting plasma insulin level and the homeostasis model assessment insulin resistance index were significantly increased by triple therapy with glibenclamide and decreased by the one with sitagliptin. Glyburide 143-156 insulin Homo sapiens 66-73 22768668-10 2012 At age 3 years 11 months, glyburide was reintroduced at a very low dose and was increased with concomitant weaning of insulin over the following 6 months. Glyburide 26-35 insulin Homo sapiens 118-125 23179858-7 2013 Drug effects that increased insulin secretion resulted in the best model fit, thus identifying the primary mechanism of action of Gb and metabolites as insulin secretagogues. Glyburide 130-132 insulin Homo sapiens 28-35 23179858-9 2013 The semi-mechanistic IGI model was successfully applied to MTT data and identified the primary mechanism of action for Gb, quantifying its effects on glucose and insulin time profiles. Glyburide 119-121 insulin Homo sapiens 162-169 22982177-8 2013 Treatments with GLP-1, exenatide, glyburide, nateglinide and sitagliptin effectively increased plasma human C-peptide levels and improved postprandial glucose concentrations. Glyburide 34-43 insulin Homo sapiens 108-117 20814548-8 2010 Glibenclamide also eliminated the insulin-induced changes. Glyburide 0-13 insulin Homo sapiens 34-41 21175273-5 2011 RESULTS: the 0-30 min area under the curve (AUC) for insulin was higher (glyburide, 294 +- 37 pM; repaglinide, 382 +- 39 pM) (P < 0.01), and the 180-240 min AUC for insulin was lower (glyburide, 325 +- 50 pM; repaglinide, 196 +- 20 pM) (P < 0.01) with repaglinide. Glyburide 73-82 insulin Homo sapiens 53-60 21175273-5 2011 RESULTS: the 0-30 min area under the curve (AUC) for insulin was higher (glyburide, 294 +- 37 pM; repaglinide, 382 +- 39 pM) (P < 0.01), and the 180-240 min AUC for insulin was lower (glyburide, 325 +- 50 pM; repaglinide, 196 +- 20 pM) (P < 0.01) with repaglinide. Glyburide 191-200 insulin Homo sapiens 53-60 20804735-7 2010 This contrasted with the action of the sulfonylurea glibenclamide, which also induced insulin secretion under low-glucose conditions (2.8mM). Glyburide 52-65 insulin Homo sapiens 86-93 21792527-5 2011 Treatment with both creatine and glibenclamide increased insulin and c-peptide concentrations after 120 and 240 min (p<0.05 and p<0.01). Glyburide 33-46 insulin Homo sapiens 57-64 21792527-5 2011 Treatment with both creatine and glibenclamide increased insulin and c-peptide concentrations after 120 and 240 min (p<0.05 and p<0.01). Glyburide 33-46 insulin Homo sapiens 69-78 19656320-8 2010 Pancreatic insulin disappears in an animal model of K(ATP)-induced NDM, unless glycemia is well controlled, thus, a dramatically lower glyburide requirement in the infant may reflect preserved insulin content because of early sulfonylurea intervention. Glyburide 135-144 insulin Homo sapiens 11-18 21426008-1 2010 BACKGROUND: The sulfonylureas glibenclamide and glimepiride are oral antidiabetic drugs that stimulate insulin secretion by closing pancreatic ATP-dependent potassium channels. Glyburide 30-43 insulin Homo sapiens 103-110 20540435-6 2010 Insulin therapy was successfully switched to low doses of oral glibenclamide. Glyburide 63-76 insulin Homo sapiens 0-7 19502091-5 2009 RESULTS: Insulin secretion differed significantly between study groups, with marked decreases in the presence of HG plus glibenclamide. Glyburide 121-134 insulin Homo sapiens 9-16 19502091-6 2009 Compared with NG, insulin expression decreased significantly with HG, and increased similarly with gliclazide as with glibenclamide. Glyburide 118-131 insulin Homo sapiens 18-25 18457474-13 2008 Average infant birth weight may be lower in mothers treated with insulin than with glyburide. Glyburide 83-92 insulin Homo sapiens 65-72 19295505-7 2009 Despite comparable beta-cell responsivity indices, the average beta-cell function corrected for insulin resistance was more than 3.5-fold lower in women with glyburide-treated GDM than in healthy pregnant women. Glyburide 158-167 insulin Homo sapiens 96-103 17394534-10 2008 Ratios of proinsulin to insulin were higher during treatment in glibenclamide- vs. insulin-treated patients after year 2. Glyburide 64-77 insulin Homo sapiens 10-20 17394534-10 2008 Ratios of proinsulin to insulin were higher during treatment in glibenclamide- vs. insulin-treated patients after year 2. Glyburide 64-77 insulin Homo sapiens 13-20 17394534-10 2008 Ratios of proinsulin to insulin were higher during treatment in glibenclamide- vs. insulin-treated patients after year 2. Glyburide 64-77 insulin Homo sapiens 24-31 17394534-13 2008 However, deterioration occurred faster in the glibenclamide group, indicating that alleviating demands on secretion by insulin treatment is beneficial. Glyburide 46-59 insulin Homo sapiens 119-126 19688040-7 2009 CAPN10 SNP-43 and SNP-44 were genotyped and related to gene expression and insulin release in response to glucose, arginine and glibenclamide. Glyburide 128-141 insulin Homo sapiens 75-82 18793589-12 2008 Vildagliptin/glyburide coadministration significantly reduced the area under the plasma glucose-time curve compared with glyburide alone (AUE0-5h reduced by 12% (p = 0.005) and AUE0-15h by 13% (p = 0.003)), and increased the area under the plasma insulin-time curve (AUE0-15h increased by 12% (p = 0.041)). Glyburide 13-22 insulin Homo sapiens 247-254 17980009-12 2008 Glibenclamide increased fasting insulin and the postprandial insulin AUC but had no effect on the PI and SPI AUCs. Glyburide 0-13 insulin Homo sapiens 32-39 17980009-12 2008 Glibenclamide increased fasting insulin and the postprandial insulin AUC but had no effect on the PI and SPI AUCs. Glyburide 0-13 insulin Homo sapiens 61-68 18246324-1 2008 In many countries, first- or second-line pharmacological treatment of patients with type 2 diabetes consists of sulfonylureas (such as glibenclamide [known as glyburide in the USA and Canada]), which stimulate the beta cell to secrete insulin. Glyburide 135-148 insulin Homo sapiens 235-242 18246324-1 2008 In many countries, first- or second-line pharmacological treatment of patients with type 2 diabetes consists of sulfonylureas (such as glibenclamide [known as glyburide in the USA and Canada]), which stimulate the beta cell to secrete insulin. Glyburide 159-168 insulin Homo sapiens 235-242 17652641-10 2007 Treatment of the patient with the sulfonylurea glibenclamide not only enabled insulin therapy to be stopped, but also resulted in improvement in epilepsy and psychomotor abilities. Glyburide 47-60 insulin Homo sapiens 78-85 18831351-0 2008 Relationship between plasma leptin and plasma insulin levels in type-2 diabetic patients before and after treatment with glibenclamide and glimepiride. Glyburide 121-134 insulin Homo sapiens 46-53 17385195-8 2007 Mortality for malignancies was significantly higher in patients treated with glibenclamide after adjustment for age, sex, BMI, and insulin and metformin treatment, [OR 3.6(1.1;11.9); p < 0.05]. Glyburide 77-90 insulin Homo sapiens 131-138 17316868-3 2007 Chronic exposure of pancreatic beta-cells to sulfonylureas (glibenclamide or tolbutamide) and glinide (nateglinide) similarly impaired their acute effectiveness by reducing the insulin content and the number of functional K(ATP) channels on the plasma membrane. Glyburide 60-73 insulin Homo sapiens 177-184 17728498-6 2007 Their basal c-peptide levels increased after one week of glibenclamide therapy, and one month later, the insulin and c-peptide levels were in the normal ranges without any episodes of hyper- or hypoglycemia. Glyburide 57-70 insulin Homo sapiens 12-21 17047922-6 2006 RESULTS: Glibenclamide (glyburide) treatment was started at 23 months and resulted in insulin being discontinued, lower overall glycaemia, reduced glucose fluctuations and reduced hypoglycaemia. Glyburide 9-22 insulin Homo sapiens 86-93 17596474-3 2007 A single randomized controlled trial of glyburide versus insulin indicates that glyburide treatment can provide a relatively safe alternative to insulin therapy. Glyburide 80-89 insulin Homo sapiens 57-64 17363911-9 2007 Women in the insulin group were younger (31.5+/-5.8 vs 35.2+/-4.7 years, P<0.001) and had a higher mean BMI (32.4+/-6.4 vs 29.1+/-5.8 kg/m(2), P=0.003) compared to glyburide group. Glyburide 167-176 insulin Homo sapiens 13-20 17174222-11 2007 However, rosiglitazone reduced insulin resistance and proinsulin levels whereas glibenclamide use was associated with an increase in fasting insulin and proinsulin. Glyburide 80-93 insulin Homo sapiens 153-163 17296510-15 2006 The transfer from insulin injections to oral glibenclamide therapy seems highly effective for most patients and safe. Glyburide 45-58 insulin Homo sapiens 18-25 17047922-6 2006 RESULTS: Glibenclamide (glyburide) treatment was started at 23 months and resulted in insulin being discontinued, lower overall glycaemia, reduced glucose fluctuations and reduced hypoglycaemia. Glyburide 24-33 insulin Homo sapiens 86-93 17003289-3 2006 GLP-1 similarly augmented the K(ATP) channel-independent insulin-releasing effects of tolbutamide, glibenclamide or nateglinide. Glyburide 99-112 insulin Homo sapiens 57-64 16713429-9 2006 Similarly, treatment with 5 micromol/L gliclazide or 10 mmol/L NAC significantly overcome the reduction in insulin-stimulated GLUT4 translocation by hydrogen peroxide (P<.01), whereas 5 micromol/L glibenclamide did not. Glyburide 200-213 insulin Homo sapiens 107-114 16873786-7 2006 In the A1C >9.5% arm, inhaled insulin demonstrated a significantly greater reduction in A1C than glibenclamide, between-treatment difference -0.37% (-0.62 to -0.12; P = 0.004). Glyburide 100-113 insulin Homo sapiens 33-40 16595597-12 2006 After 24-h exposure to high (16.7 mmol/liter) glucose concentration, impairment of glibenclamide-induced insulin release was significantly (P = 0.01) worse with the E23K variant. Glyburide 83-96 insulin Homo sapiens 105-112 16492219-1 2006 AIMS: The oral hypoglycaemic sulphonylurea glibenclamide stimulates endogenous insulin secretion through blockade of ATP-sensitive potassium (KATP) channels on pancreatic beta cells, but also blocks cardiovascular KATP channels, leading to increased peripheral vascular resistance and reduced peripheral blood flow in non-diabetic subjects. Glyburide 43-56 insulin Homo sapiens 79-86 16738156-10 2006 CONCLUSION: Glyburide was more likely to fail in women diagnosed earlier in pregnancy, of older age and multiparity, and with higher fasting glucoses, suggesting that earlier glucose intolerance and a reduced capacity to respond to an insulin secretagogue may distinguish this group. Glyburide 12-21 insulin Homo sapiens 235-242 16492219-11 2006 Glibenclamide produced an 8-fold increase in circulating insulin compared with placebo (P < 0.001). Glyburide 0-13 insulin Homo sapiens 57-64 16324923-6 2006 Despite lower plasma glucose levels, glyburide stimulated insulin secretion during this period (0.89 +/- 0.13 vs 1.47 +/- 0.15 pmol x kg(-1) x min(-1), control vs glyburide; P = .001), whereas glimepiride did not (P = .08). Glyburide 37-46 insulin Homo sapiens 58-65 16443858-2 2006 RESEARCH DESIGN AND METHODS: We compared the acute effect of nateglinide, glibenclamide, and placebo on prandial plasma glucose and serum insulin, C-peptide, and glucagon excursions in 15 patients with MODY3. Glyburide 74-87 insulin Homo sapiens 138-145 16475928-4 2006 Blockers of Kir6.2/SUR1 channels, e.g. glibenclamide and repaglinide stimulate release of insulin and are used for treatment of type 2 diabetes. Glyburide 39-52 insulin Homo sapiens 90-97 16380479-8 2006 In conclusion, chronic exposure to glibenclamide results in degranulation of a subpopulation of beta-cells, which maintain an elevated protein and insulin synthetic activity irrespective of the presence of the drug and of glucose. Glyburide 35-48 insulin Homo sapiens 147-154 16324923-8 2006 In contrast, during recovery from hypoglycemia, glyburide but not glimepiride inappropriately stimulates insulin secretion at low plasma glucose levels. Glyburide 48-57 insulin Homo sapiens 105-112 16324923-9 2006 This differential effect on insulin secretion may be an important factor in explaining why glyburide causes severe hypoglycemia more frequently than glimepiride. Glyburide 91-100 insulin Homo sapiens 28-35 15912128-1 2005 Sulfonylurea drugs, like glibenclamide, stimulate insulin secretion by blocking ATP-sensitive potassium channels on pancreatic beta cells. Glyburide 25-38 insulin Homo sapiens 50-57 15642492-9 2005 Quantitative RT-PCR studies showed that, compared with the control islets, cells preincubated with glibenclamide or chlorpropamide had an increased expression of insulin mRNA, with no change in the expression of GLUT-1. Glyburide 99-112 insulin Homo sapiens 162-169 15672015-1 2005 OBJECTIVE: We sought to investigate the association between glyburide dose, degree of severity in gestational diabetes mellitus (GDM), level of glycemic control, and pregnancy outcome in insulin- and glyburide-treated patients. Glyburide 60-69 insulin Homo sapiens 187-194 15230648-14 2004 The reference compound glibenclamide increased insulin and decreased glucose levels as expected. Glyburide 23-36 insulin Homo sapiens 47-54 15579757-7 2004 In contrast, glyburide significantly increased both plasma PI (45%; P < 0.001) and the PI:IRI ratio (10%) (P < 0.05 vs. baseline). Glyburide 13-22 insulin Homo sapiens 59-61 15579757-7 2004 In contrast, glyburide significantly increased both plasma PI (45%; P < 0.001) and the PI:IRI ratio (10%) (P < 0.05 vs. baseline). Glyburide 13-22 insulin Homo sapiens 90-92 15579757-8 2004 These results show that rosiglitazone and glyburide have differential effects on absolute PI levels and the PI:IRI ratio in people with type 2 diabetes. Glyburide 42-51 insulin Homo sapiens 90-92 15579757-8 2004 These results show that rosiglitazone and glyburide have differential effects on absolute PI levels and the PI:IRI ratio in people with type 2 diabetes. Glyburide 42-51 insulin Homo sapiens 108-110 15243303-0 2004 Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. Glyburide 30-43 insulin Homo sapiens 152-159 15563963-5 2004 These findings suggest that glimepiride improves insulin resistance in hyperinsulinemic patients treated with glibenclamide. Glyburide 110-123 insulin Homo sapiens 49-56 15375790-9 2004 Plasma insulin levels were significantly higher from 100 to 240 minutes after clamp termination in patients given glyburide versus nateglinide. Glyburide 114-123 insulin Homo sapiens 7-14 15133754-5 2004 Fasting insulin was not significantly increased by any treatment; 24-h insulin was not increased by glipizide GITS AM, but was elevated by glipizide GITS PM (39%, p < 0.05) and glibenclamide (23%, p < 0.05). Glyburide 180-193 insulin Homo sapiens 71-78 15133755-6 2004 RESULTS: Neutrophil-transendothelial migration and PECAM-1 expression were enhanced by insulin (100 micro U/mL, 24 h) and were attenuated by gliclazide (20 micro M), but not by other K(ATP) channel blockers (glibenclamide, nateglinide, and glimepiride). Glyburide 208-221 insulin Homo sapiens 87-94 14746575-5 2004 RESULTS: Mean peak serum insulin levels were lower after nateglinide (115 mU/l) than after glibenclamide (145 mU/l.h; p = 0.017) but higher than after placebo (79 mU/l; p = 0.001). Glyburide 91-104 insulin Homo sapiens 25-32 14746575-7 2004 Total insulin exposure over the day was higher after glibenclamide compared with that following nateglinide (1216 vs. 1067 mU/l.h; p = 0.009). Glyburide 53-66 insulin Homo sapiens 6-13 14715864-0 2004 The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency. Glyburide 26-39 insulin Homo sapiens 4-11 14709397-7 2004 RESULTS: Both neutrophil adhesion and ICAM-1 expression enhanced by high insulin (100 microU/ml, 48 h) were attenuated by gliclazide (20 microM), but not by other K(ATP) channel blockers (glibenclamide, nateglinide, and glimepiride). Glyburide 188-201 insulin Homo sapiens 73-80 15260389-0 2003 Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy. Glyburide 67-80 insulin Homo sapiens 135-142 14565810-11 2003 However, the daily insulin dose alone was significantly lower (p < 0.05) with glimepiride (0.49 +/- 0.10; mean +/- SE) than with other sulfonylureas (tolazamide 0.58 +/- 0.12, glyburide 0.59 +/- 0.12, glipizide GITS 0.59 +/- 0.14). Glyburide 179-188 insulin Homo sapiens 19-26 15260389-12 2003 CONCLUSIONS: With proper patient selection, pioglitazone with glibenclamide and metformin can be safely used in patients receiving insulin with good results. Glyburide 62-75 insulin Homo sapiens 131-138 12958175-12 2003 Furthermore, glibenclamide (20 microM) also stimulated the release of insulin from fluorescently labeled secretion granules, and diazoxide (150 microM) blocked that stimulated release of insulin. Glyburide 13-26 insulin Homo sapiens 70-77 15000437-0 2003 The combination metformin/glyburide exerts its hypoglycemic effect mainly by increasing insulin secretion: a controlled, randomized, double-blind, crossover study. Glyburide 26-35 insulin Homo sapiens 88-95 15000437-11 2003 Increased insulin secretion was the explanation for the additive effects of the combination (percentual change in acute insulin response during the minimal model = 5.8 vs 51.5 vs 88.2% for metformin, glyburide and the combination, p < 0.05). Glyburide 200-209 insulin Homo sapiens 10-17 15000437-13 2003 In conclusion, the additive hypoglycemic effects of the combination glyburide/metformin was caused by increased insulin secretion. Glyburide 68-77 insulin Homo sapiens 112-119 12882841-5 2003 RESULTS: After 1 year the glucagon-stimulated C-peptide response was increased in the insulin-treated group by 0.14 +/- 0.08 nmol/l, whereas it was decreased by 0.12 +/- 0.08 nmol/l in the glibenclamide group, P < 0.02 for difference between groups. Glyburide 189-202 insulin Homo sapiens 86-93 12958175-7 2003 Using radioimmunoassay techniques, we report that exposure of the cells to tolbutamide (100 microM) resulted in an increase in insulin secretion from 0.3 +/- 0.05 to 1.8 +/- 0.2 pmol insulin/10(6) cells and glibenclamide (20 microM) from 0.4 +/- 0.06 to 2.1 +/- 0.3 (n=4), similar to what is seen on glucose (20 mM) stimulation. Glyburide 207-220 insulin Homo sapiens 127-134 12684219-4 2003 However, recent reports show that >90% of glibenclamide-binding sites are localized intracellularly and that the drug can stimulate insulin release independently of changes in KATP channels and cytoplasmic free Ca2+. Glyburide 45-58 insulin Homo sapiens 135-142 12684219-5 2003 Also, glibenclamide specifically and progressively accumulates in islets in association with secretory granules and mitochondria and causes long-lasting insulin secretion. Glyburide 6-19 insulin Homo sapiens 153-160 12684219-11 2003 We suggest that chronic CPT inhibition, through the progressive islet accumulation of glibenclamide, may explain the prolonged stimulation of insulin secretion in some diabetic patients even after drug removal that contributes to the sustained hypoglycemia of the sulfonylurea. Glyburide 86-99 insulin Homo sapiens 142-149 12882841-6 2003 After 2 years, fasting insulin levels were higher after treatment withdrawal in the insulin-treated versus the glibenclamide-treated group (P = 0.02). Glyburide 111-124 insulin Homo sapiens 23-30 12795025-4 2003 Among insulin secretizers repaglinid, glibenclamid and glipizide have an ATP-sensitive potassium channel inhibiting effect in the vascular smooth muscle cells, too, reducing hereby vasodilation. Glyburide 38-50 insulin Homo sapiens 6-13 12877648-2 2003 A new single-tablet of glyburide/metformin combination therapy (Glucovance), Bristol-Myers Squibb, Inc.) has recently been developed, which addresses the primary defects of Type 2 diabetes: beta-cell dysfunction and insulin resistance. Glyburide 23-32 insulin Homo sapiens 216-223 12047399-1 2002 OBJECTIVE: To evaluate whether simultaneous initial treatment of both insulin resistance and impaired beta-cell insulin secretion with glyburide/metformin tablets is superior to monotherapy with each component agent. Glyburide 135-144 insulin Homo sapiens 112-119 12589230-3 2003 Patients on monotherapy might benefit from a combination agent such as glyburide/metformin, which increases insulin secretion and reduces insulin resistance. Glyburide 71-80 insulin Homo sapiens 108-115 12173728-0 2002 The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Glyburide 54-67 insulin Homo sapiens 96-103 12746761-7 2003 LP versus GB induced changes from baseline to endpoint in fasting C-peptide (nmol/L), proinsulin and insulin levels (pmol/L) were - 0.2 +/- 0.4 versus - 0.1 +/- 0.6 (p = 0.04), - 11.2 +/- 26.0 versus - 1.1 +/- 17.3 (p = 0.03), and - 27.8 +/- 147.4 versus + 32.6 +/- 286.2 (not significant), respectively. Glyburide 10-12 insulin Homo sapiens 86-96 12746761-7 2003 LP versus GB induced changes from baseline to endpoint in fasting C-peptide (nmol/L), proinsulin and insulin levels (pmol/L) were - 0.2 +/- 0.4 versus - 0.1 +/- 0.6 (p = 0.04), - 11.2 +/- 26.0 versus - 1.1 +/- 17.3 (p = 0.03), and - 27.8 +/- 147.4 versus + 32.6 +/- 286.2 (not significant), respectively. Glyburide 10-12 insulin Homo sapiens 89-96 12606519-4 2003 The fluorescent glibenclamides colocalize with Ins-C-GFP, a live-cell fluorescent reporter of insulin granules. Glyburide 16-30 insulin Homo sapiens 94-101 12803736-8 2003 Metformin (an insulin sensitiser) and glibenclamide (an insulin secretagogue) are well supported by decades of clinical evidence, and the pharmacokinetics of these agents support twice-daily co-administration. Glyburide 38-51 insulin Homo sapiens 56-63 12542723-0 2003 Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Glyburide 40-53 insulin Homo sapiens 57-64 12542723-1 2003 AIM: The aim of our double-blind, placebo-controlled study was to compare the effect of acarbose and glibenclamide on the insulin sensitivity in type 2 diabetes. Glyburide 101-114 insulin Homo sapiens 122-129 12542723-11 2003 The fasting insulin levels remained unchanged in all three groups, whereas postprandial insulin values increased significantly under glibenclamide. Glyburide 133-146 insulin Homo sapiens 88-95 11850098-0 2002 Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. Glyburide 34-47 insulin Homo sapiens 51-61 12186116-12 2002 In subjects controlled on a single dose of insulin with glibenclamide it is preferable to give an evening dose rather than a morning dose. Glyburide 56-69 insulin Homo sapiens 43-50 11956512-10 2002 Correspondingly, insulin secretion measured within 12 hours after glyburide ingestion was higher in carriers of the genotype *3/*3 compared with the other genotypes (P =.028), whereas the differences in glucose concentrations were not significant. Glyburide 66-75 insulin Homo sapiens 17-24 11850098-0 2002 Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. Glyburide 34-47 insulin Homo sapiens 54-61 11850098-5 2002 The breakfast increment of proinsulin was lower with acarbose than glibenclamide (6.8 vs. 19.3 pmol/l, P<0.05) as was the level at that time (37.3 +/- 5.3 vs. 56.4 +/- 7.5 pmol/l, P<0.05). Glyburide 67-80 insulin Homo sapiens 27-37 11850098-6 2002 A lower AUC of insulin after treatment was also observed with acarbose than glibenclamide (7.9 +/- 0.9 vs. 14.8 +/- 4.5 nmol/l per h, P<0.05), as also for 1-h increment (81 +/- 26, vs. 380 +/- 120 pmol/l, P<0.01) and 1-h level (325 +/- 30 vs. 621 +/- 132 pmol/l, P<0.01). Glyburide 76-89 insulin Homo sapiens 15-22 11850098-8 2002 CONCLUSIONS: Measurement of circadian excursions of proinsulin and insulin reveals distinct differences in meal-time proinsulin and insulin increment and level between acarbose and glibenclamide whereas fasting levels of these insulin fractions remained unaffected. Glyburide 181-194 insulin Homo sapiens 52-62 11850098-8 2002 CONCLUSIONS: Measurement of circadian excursions of proinsulin and insulin reveals distinct differences in meal-time proinsulin and insulin increment and level between acarbose and glibenclamide whereas fasting levels of these insulin fractions remained unaffected. Glyburide 181-194 insulin Homo sapiens 55-62 11850098-8 2002 CONCLUSIONS: Measurement of circadian excursions of proinsulin and insulin reveals distinct differences in meal-time proinsulin and insulin increment and level between acarbose and glibenclamide whereas fasting levels of these insulin fractions remained unaffected. Glyburide 181-194 insulin Homo sapiens 117-127 11850098-8 2002 CONCLUSIONS: Measurement of circadian excursions of proinsulin and insulin reveals distinct differences in meal-time proinsulin and insulin increment and level between acarbose and glibenclamide whereas fasting levels of these insulin fractions remained unaffected. Glyburide 181-194 insulin Homo sapiens 67-74 11739446-6 2001 Both nateglinide and glyburide enhanced glucose-induced insulin release, compared with placebo (area under the curve -15-300 min: nateglinide 23,595 +/- 11,212 pM/min, glyburide 54,556 +/- 15,253 pM/min, placebo 10,242 +/- 2,414 pM/min). Glyburide 21-30 insulin Homo sapiens 56-63 11751665-6 2002 RESULTS: One hour after glibenclamide, serum insulin increased from (mean (SD)) 7.4 (2.0) to 44.8 (25.5) mU/l (p < 0.005), and C peptide from 1.4 (0.4) to 3.4 (1.2) ng/l (p = 0.005). Glyburide 24-37 insulin Homo sapiens 45-52 11751665-11 2002 CONCLUSIONS: Glibenclamide, 0.05 mg/kg intravenously, is effective in increasing serum insulin, suggesting a K(ATP) channel blocking effect in pancreatic beta cells. Glyburide 13-26 insulin Homo sapiens 87-94 11815472-2 2002 Insulin secretion was then assessed in response to glucose (16.7 mmol/l), arginine (20 mmol/l), and glyburide (200 micromol/l) during static incubation or by perifusion. Glyburide 100-109 insulin Homo sapiens 0-7 12390047-9 2002 However, OAHAs, especially glibenclamide (glyburide), may be beneficial in a situation where the proper use of insulin is problematic. Glyburide 27-40 insulin Homo sapiens 111-118 12390047-9 2002 However, OAHAs, especially glibenclamide (glyburide), may be beneficial in a situation where the proper use of insulin is problematic. Glyburide 42-51 insulin Homo sapiens 111-118 11903411-9 2001 RESULTS: There were significant correlations between daily Gb dose, on the one hand, and, on the other, HbAlc (r = 0.55), Delta-insulin (r = - 0.59) and Delta-proinsulin (r = - 0.52) levels. Glyburide 59-61 insulin Homo sapiens 159-169 11903411-10 2001 Significant correlations between Gb therapy duration and insulin (r = - 0.40) and proinsulin (r = - 0.34) secretion and between Gb dose and ratio proinsulin/insulin (RPI) at both time points (r = 0.32 and 0.30) were also found. Glyburide 33-35 insulin Homo sapiens 57-64 11903411-14 2001 CONCLUSIONS: Our results indicate that, in patients on chronic medication, Gb is capable of stimulating both insulin and proinsulin secretion; the effect on insulin release is relatively greater. Glyburide 75-77 insulin Homo sapiens 109-116 11903411-14 2001 CONCLUSIONS: Our results indicate that, in patients on chronic medication, Gb is capable of stimulating both insulin and proinsulin secretion; the effect on insulin release is relatively greater. Glyburide 75-77 insulin Homo sapiens 121-131 11903411-14 2001 CONCLUSIONS: Our results indicate that, in patients on chronic medication, Gb is capable of stimulating both insulin and proinsulin secretion; the effect on insulin release is relatively greater. Glyburide 75-77 insulin Homo sapiens 124-131 11739446-9 2001 The enhancement of insulin release by glyburide resulted in a lower minimal glucose concentration with glyburide (3.8 +/- 0.2 mM), compared with nateglinide (5.0 +/- 0.2 mM) and placebo (5.9 +/- 0.2 mM). Glyburide 38-47 insulin Homo sapiens 19-26 11739446-9 2001 The enhancement of insulin release by glyburide resulted in a lower minimal glucose concentration with glyburide (3.8 +/- 0.2 mM), compared with nateglinide (5.0 +/- 0.2 mM) and placebo (5.9 +/- 0.2 mM). Glyburide 103-112 insulin Homo sapiens 19-26 11739446-11 2001 Further, the differences in the kinetics of nateglinide and glyburide action results in continued insulin release with glyburide despite the fact that glucose levels have returned to basal, thus resulting in a further reduction in glucose levels and a lower nadir. Glyburide 60-69 insulin Homo sapiens 98-105 11739446-11 2001 Further, the differences in the kinetics of nateglinide and glyburide action results in continued insulin release with glyburide despite the fact that glucose levels have returned to basal, thus resulting in a further reduction in glucose levels and a lower nadir. Glyburide 119-128 insulin Homo sapiens 98-105 11356916-1 2001 Insulin secretion from MIN6 cells (a pancreatic beta-cell line) induced by high glucose (greater than 16.8 mM) was potentiated by a novel hypoglycemic agent [trans-4-(4-methylcyclohexyl)-4-oxobutyric acid (JTT-608)] (but not glibenclamide, a sulfonylurea). Glyburide 225-238 insulin Homo sapiens 0-7 11523909-5 2001 PCO-400 and nicorandil dose-dependently inhibited insulin-stimulated glucose uptake, and their inhibitory effects were reversed by glibenclamide or gliclazide. Glyburide 131-144 insulin Homo sapiens 50-57 11375357-10 2001 h/l, P < 0.01), and only glyburide increased fasting insulin levels. Glyburide 28-37 insulin Homo sapiens 56-63 11344200-7 2001 Hence, our results show that at a blood glucose concentration of 5 mmol/L, GIP augments the increase in plasma insulin levels stimulated by glibenclamide, possibly acting through a mechanism involving decreased insulin extraction in the liver or peripheral tissues, thus increasing insulin availability. Glyburide 140-153 insulin Homo sapiens 111-118 11344200-0 2001 Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction. Glyburide 80-93 insulin Homo sapiens 18-25 11305519-7 2001 RESULTS: Glibenclamide (i.e. glibenclamide plus glucose) significantly increased plasma insulin concentrations and glycemia while placebo (i.e. glucose alone) significantly increased glycemia but did not change plasma insulin levels. Glyburide 9-22 insulin Homo sapiens 88-95 11344200-4 2001 We now show that an infusion of GIP in healthy volunteers in whom blood glucose levels were maintained at 5 mmol/L, increased glibenclamide-stimulated levels of plasma insulin without significantly changing the C peptide profile. Glyburide 126-139 insulin Homo sapiens 168-175 11305519-7 2001 RESULTS: Glibenclamide (i.e. glibenclamide plus glucose) significantly increased plasma insulin concentrations and glycemia while placebo (i.e. glucose alone) significantly increased glycemia but did not change plasma insulin levels. Glyburide 29-42 insulin Homo sapiens 88-95 11090651-2 2000 In acute 20-min incubations, 200 microM of tolbutamide or glibenclamide stimulated insulin release from non-depolarized and depolarized cells, which was dramatically reduced following 18-h culture with 100 microM glibenclamide. Glyburide 58-71 insulin Homo sapiens 83-90 12622887-6 2001 The association biguanides and S, in particular glibenclamide plus metformin, is now widely used by diabetologists in SF since glibenclamide improves insulin secretion while metformin exerts its antidiabetic. Glyburide 48-61 insulin Homo sapiens 150-157 12622887-6 2001 The association biguanides and S, in particular glibenclamide plus metformin, is now widely used by diabetologists in SF since glibenclamide improves insulin secretion while metformin exerts its antidiabetic. Glyburide 127-140 insulin Homo sapiens 150-157 11090651-2 2000 In acute 20-min incubations, 200 microM of tolbutamide or glibenclamide stimulated insulin release from non-depolarized and depolarized cells, which was dramatically reduced following 18-h culture with 100 microM glibenclamide. Glyburide 213-226 insulin Homo sapiens 83-90 11090651-4 2000 However, desensitization of insulinotropic effects of sulphonylureas in depolarized cells following glibenclamide culture and associated decline in cellular insulin content was not fully reversible. Glyburide 100-113 insulin Homo sapiens 28-35 11036118-9 2000 Eight women in the glyburide group (4 percent) required insulin therapy. Glyburide 19-28 insulin Homo sapiens 56-63 11257323-11 2000 Insulin resistance measured by the homeostasis model decreased more in the metformin group than in the glibenclamide group. Glyburide 103-116 insulin Homo sapiens 0-7 10789825-8 2000 The reasons for this are unclear, but the more abnormal pattern of insulin release produced by glibenclamide may be partly responsible and, indeed, may explain the increased risk of hypoglycaemia with this agent. Glyburide 95-108 insulin Homo sapiens 67-74 11225657-0 2000 Erythrocyte insulin receptor tyrosine kinase activity is increased in glyburide-treated patients with type 2 diabetes in good glycaemic control. Glyburide 70-79 insulin Homo sapiens 12-19 11225657-1 2000 AIM: The goal of this study was to test the hypothesis that insulin receptor tyrosine kinase activity of isolated erythrocytes would be greater in glyburide-treated patients with type 2 diabetes in good glycaemic control (n = 13) than in untreated patients (n = 12) with significant fasting hyperglycaemia. Glyburide 147-156 insulin Homo sapiens 60-67 11225657-5 2000 In addition, insulin-stimulated tyrosine kinase activity was increased in erythrocytes from glyburide -treated patients (p < 0.01). Glyburide 92-101 insulin Homo sapiens 13-20 10872292-6 2000 Among the stimulators of insulin secretion are the sulfonylureas (e.g. glibenclamide, glibonuride, glisoxepid, glimepiride), and the so-called prandial glucose regulators, such as repaglinide, which differ from the sulfonylureas both chemically and in their pharmacodynamic properties. Glyburide 71-84 insulin Homo sapiens 25-32 10566126-0 1999 The effect of octreotide on glucose and insulin levels in a patient with type 2 diabetes on glibenclamide. Glyburide 92-105 insulin Homo sapiens 40-47 10594485-10 1999 Glibenclamide had the expected effect on insulin and glucose levels independent of comedication. Glyburide 0-13 insulin Homo sapiens 41-48 10663449-1 2000 OBJECTIVE: We analysed the kinetics and effects of glibenclamide (Gb) on glucose, insulin and proinsulin secretion in two ethnic groups (10 in each) of type-2 diabetic patients, one of Caucasian, the other of Chinese origin. Glyburide 66-68 insulin Homo sapiens 94-104 10663449-12 2000 When Gb was administered, the plasma glucose increases were reduced, and the increases of serum insulin and proinsulin levels were greater in both ethnic groups. Glyburide 5-7 insulin Homo sapiens 96-103 10663449-12 2000 When Gb was administered, the plasma glucose increases were reduced, and the increases of serum insulin and proinsulin levels were greater in both ethnic groups. Glyburide 5-7 insulin Homo sapiens 108-118 10663449-20 2000 Gb augmented glucose-induced release of both insulin and proinsulin in both ethnic groups; the effect on insulin secretion was more pronounced. Glyburide 0-2 insulin Homo sapiens 45-52 10663449-20 2000 Gb augmented glucose-induced release of both insulin and proinsulin in both ethnic groups; the effect on insulin secretion was more pronounced. Glyburide 0-2 insulin Homo sapiens 57-67 10526729-4 1999 Plasma insulin concentrations were always increased by glibenclamide, and they were lowered identically by exercise with and without glibenclamide. Glyburide 55-68 insulin Homo sapiens 7-14 10526729-5 1999 However, throughout exercise, absolute concentrations of insulin were lower on days without glibenclamide compared with days with glibenclamide (34.5 +/- 4.7 vs. 47.4 +/- 5.5 pmol/l; P < 0.05). Glyburide 92-105 insulin Homo sapiens 57-64 10526729-12 1999 The interaction reflects an increased inhibition by glibenclamide-enhanced insulin levels of hepatic glucose production when hepatic glucose production is accelerated by exercise. Glyburide 52-65 insulin Homo sapiens 75-82 10487677-0 1999 Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. Glyburide 5-18 insulin Homo sapiens 56-63 10509738-5 1999 These findings suggest a much higher affinity of glibenclamide than S21403 for the artificial phospholipid bilayer, this coinciding with a higher biological potency, as insulin secretagogue, of the hypoglycemic sulfonylurea as compared to meglitinide analog. Glyburide 49-62 insulin Homo sapiens 169-176 10543431-7 1999 Glibenclamide, which was antifibrillatory at 0.3 mg/kg and 1 mg/kg, increased plasma insulin and lowered blood glucose already at a dose as low as 0.01 mg/kg. Glyburide 0-13 insulin Homo sapiens 85-92 10614063-8 1999 CONCLUSIONS: The postprandial levels of glucose, triglycerides, fibrinogen, F1.2, TAT and d-dimers were lower after glibenclamide administration as compared to placebo, while the concentrations of insulin and c-peptide were higher. Glyburide 116-129 insulin Homo sapiens 197-204 10614063-8 1999 CONCLUSIONS: The postprandial levels of glucose, triglycerides, fibrinogen, F1.2, TAT and d-dimers were lower after glibenclamide administration as compared to placebo, while the concentrations of insulin and c-peptide were higher. Glyburide 116-129 insulin Homo sapiens 209-218 10193691-5 1999 Serum insulin levels were lower with troglitazone than with glibenclamide. Glyburide 60-73 insulin Homo sapiens 6-13 10543411-12 1999 Despite this C-peptide was significantly higher (p < 0.002) glibenclamide (5.7 +/- 1.5 ng/ml) compared to glimepiride (5.1 +/- 1.3 ng/ml); the trend was the same for insulin but the results were not significantly different (p = 0.06) In conclusion, in the fasting state, glimepiride and glibenclamide had similar effects on the changes in blood glucose levels after i.v. Glyburide 63-76 insulin Homo sapiens 13-22 9589648-7 1998 Postprandial insulin levels were significantly greater than placebo and miglitol in the glyburide group (P < 0.01). Glyburide 88-97 insulin Homo sapiens 13-20 9867217-8 1998 Insulin secretion stimulated by glibenclamide, KCl or CRF was further enhanced by the addition of 25 mmol/l glucose in AtT20HI-GLUT2-GK-6 cells but not in AtT20HI cells. Glyburide 32-45 insulin Homo sapiens 0-7 9658206-11 1998 In normokalemic animals, insulin applied in vitro to the muscles induced a glybenclamide-sensitive hyperpolarization of the fibers and also stimulated the sarcolemmal ATP-sensitive K+ channels. Glyburide 75-88 insulin Homo sapiens 25-32 16801070-3 1999 Platelet aggregation stimulated with <0.5 U/ml thrombin, 0.75-3 microM adenosine diphosphate (ADP) or 1 microg/ml collagen was significantly lower in glyburide-treated platelets, but not in insulin-treated platelets, than in untreated ones (control). Glyburide 153-162 insulin Homo sapiens 193-200 11091663-4 1998 Insulin therapy was thought to be necessary because treatment with glibenclamide was not effective. Glyburide 67-80 insulin Homo sapiens 0-7 9589648-11 1998 The greater HbA1c reductions seen with once-a-day glyburide occurred at a cost of significant increases in weight, insulin levels, and the incidences of clinical and subclinical hypoglycemia, which did not occur in the miglitol groups. Glyburide 50-59 insulin Homo sapiens 115-122 9322807-3 1997 Sulfonylureas (e.g., glyburide), which stimulate insulin secretion, have been reported either to increase or not to affect arterial pressure, whereas nonsulfonylurea agents with insulin-sensitizing properties, the biguanide metformin and various thiazolidinediones (eg, pioglitazone), have been reported to decrease arterial pressure in humans and rodents. Glyburide 21-30 insulin Homo sapiens 49-56 9797183-4 1998 RESULTS: Administration of glibenclamide produced significantly better glycaemic control than placebo (fasting blood glucose level 8.5 +/- 2.4 versus 13.5 +/- 4.5 mmol/l, P < 0.001) and plasma insulin levels were significantly higher during glibenclamide treatment than they were with placebo (12.9 +/- 4.4 versus 9.2 +/- 4.1 mU/l, P < 0.05). Glyburide 27-40 insulin Homo sapiens 196-203 9571356-10 1998 Ventricular fibrillation in diabetic patients taking glibenclamide (11.8%) was similar to that of nondiabetic patients (11.0%) but was lower than that for those patients taking either gliclazide (18.0%; 0.1 > P > 0.05) or insulin (22.8%; P < 0.05). Glyburide 53-66 insulin Homo sapiens 228-235 9545119-8 1998 If patients rested after administration of glibenclamide serum insulin levels rose and remained elevated. Glyburide 43-56 insulin Homo sapiens 63-70 9545119-9 1998 When exercise and glibenclamide were combined the rise in serum insulin levels was blunted and insulin levels fell once exercise was begun. Glyburide 18-31 insulin Homo sapiens 64-71 9545119-9 1998 When exercise and glibenclamide were combined the rise in serum insulin levels was blunted and insulin levels fell once exercise was begun. Glyburide 18-31 insulin Homo sapiens 95-102 9545119-10 1998 Thus, exercise attenuates the glibenclamide induced increase in serum insulin in moderately hyperglycaemic Type 2 diabetic patients. Glyburide 30-43 insulin Homo sapiens 70-77 15251771-9 1997 CONCLUSION: In patients with NIDDM and good glycemic control with insulin treatment, a glyburide-related increase in endogenous insulin secretion caused a proportionate decrease in exogenous insulin requirements. Glyburide 87-96 insulin Homo sapiens 66-73 15251771-9 1997 CONCLUSION: In patients with NIDDM and good glycemic control with insulin treatment, a glyburide-related increase in endogenous insulin secretion caused a proportionate decrease in exogenous insulin requirements. Glyburide 87-96 insulin Homo sapiens 128-135 9440664-11 1998 Plasma glucose level was decreased (nadir, 4.9 mmol/L [88 mg/dL] for a 20-mg dose of glyburide vs 8.3 mmol/L [150 mg/dL] for placebo; nadir, 5.8 mmol/L [105 mg/dL] for a 20-mg dose of glipizide GITS vs 8.7 mmol/L [157 mg/dL] for placebo), and serum insulin was increased in the sulfonylurea studies compared with placebo (P<.001). Glyburide 85-94 insulin Homo sapiens 249-256 9463023-10 1997 As a function of their action period and possibly of intrinsic properties, some sulfonamides more than others (e.g. glibenclamide) affect fasting hepatic glucose production, which is particularly increased early in the day in non-insulin-dependent diabetic patients because of a circadian drop in insulin sensitivity (dawn phenomenon). Glyburide 116-129 insulin Homo sapiens 297-304 9364411-5 1997 Glibenclamide (2.5, 5.0 and 10.0 mg kg-1) dose-dependently reduced glucose and glucagon levels, and increased that of insulin in normal and diabetic rats. Glyburide 0-13 insulin Homo sapiens 118-125 9364411-6 1997 Simultaneous treatment of normal and diabetic rats with the plant extract (0.5, 2.0 and 5.0 g kg-1) and glibenclamide (5.0 mg kg-1) significantly exacerbated the effects on glucose, insulin and glucagon induced by the extract or by glibenclamide when given separately. Glyburide 104-117 insulin Homo sapiens 182-189 9322807-8 1997 Conversely, glyburide induced an accentuating action of insulin on potassium-mediated contractions. Glyburide 12-21 insulin Homo sapiens 56-63 9283792-0 1997 Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM. Glyburide 0-13 insulin Homo sapiens 88-95 9283792-1 1997 OBJECTIVE: To hypothesize if glibenclamide, which increases insulin levels, also increases leptin concentrations. Glyburide 29-42 insulin Homo sapiens 60-67 9283792-5 1997 Differing effects can be expected, since glibenclamide acts via stimulation of insulin secretion, whereas acarbose inhibits alpha-glucosidases of the small intestine and has no direct effect on insulin levels. Glyburide 41-54 insulin Homo sapiens 79-86 9283792-14 1997 CONCLUSIONS: Glibenclamide increases circadian leptin and insulin concentrations, whereas acarbose does not. Glyburide 13-26 insulin Homo sapiens 58-65 9175727-0 1997 3-Morpholinosydnonimine as instigator of a glibenclamide-sensitive reduction in the insulin secretory rate. Glyburide 43-56 insulin Homo sapiens 84-91 9279533-0 1997 Effect of glibenclamide on insulin release at moderate and high blood glucose levels in normal man. Glyburide 10-23 insulin Homo sapiens 27-34 9279533-2 1997 We studied the effect of glibenclamide on insulin secretion at submaximally and maximally stimulating blood glucose levels with a primed hyperglycaemic glucose clamp. Glyburide 25-38 insulin Homo sapiens 42-49 9279533-6 1997 However, glibenclamide led to a significantly larger increase in AUC delta insulin from 30 to 120 min (second phase): 16087 +/- 4489 vs. 7107 +/- 1533 pmol L-1 x 90 min (with and without glibenclamide respectively, P < 0.03). Glyburide 9-22 insulin Homo sapiens 75-82 9279533-13 1997 In conclusion, glibenclamide increases second-phase insulin secretion only at a submaximally stimulating blood glucose level without enhancement of first-phase insulin release and has no additive effect on insulin secretion at maximally stimulating blood glucose levels. Glyburide 15-28 insulin Homo sapiens 52-59 9059770-1 1997 Insulin-requiring diabetes (IRD) is a condition of permanent blood glucose imbalance which occurs despite a regulated diet and treatment with maximum doses of oral anti-diabetic drugs (glibenclamide 15 mg/d + metformin 1,700 mg/d). Glyburide 185-198 insulin Homo sapiens 0-7 9134058-0 1997 Effects of glibenclamide and metformin (alone or in combination) on insulin release from isolated human pancreatic islets. Glyburide 11-24 insulin Homo sapiens 68-75 9134058-2 1997 At 3.3 mmol/l glucose level, the addition of 5.0 mumol/l glibenclamide or 5.0 mumol/l glibenclamide plus 200 mumol/l metformin caused a significant increase of insulin release, compared with glucose alone. Glyburide 57-70 insulin Homo sapiens 160-167 9134058-2 1997 At 3.3 mmol/l glucose level, the addition of 5.0 mumol/l glibenclamide or 5.0 mumol/l glibenclamide plus 200 mumol/l metformin caused a significant increase of insulin release, compared with glucose alone. Glyburide 86-99 insulin Homo sapiens 160-167 8842604-14 1996 GLP-I, glibenclamide, and combined treat-stimulated meal-induced insulin release as reflected by insulinogenic indexes (control 1.44 +/- 0.4; GLP-I 6.3 +/- 1.6, P < 0.01; glibenclamide 6.8 +/- 2.1, P < 0.01; combination 20.7 +/- 5.0, P < 0.001). Glyburide 174-187 insulin Homo sapiens 65-72 8911981-9 1996 Glimepiride and glibenclamide stimulated beta-cell secretion and in the basal state both beta-cell secretory products insulin and C-peptide, were elevated in the plasma (basal C-peptide concentration: glimepiride v. placebo, 0.79 +/- 0.08 v. 0.68 +/- 0.07 nmol/l, p < 0.01; glibenclamide v. placebo, 0.79 +/- 0.07 v. 0.68 +/- 0.07 nmol/l, p < 0.004). Glyburide 16-29 insulin Homo sapiens 118-125 9072666-4 1996 Glibenclamide stimulates insulin release by pancreatic beta cells (pancreatic attachment point), while metformin acts at a peripheral level by increasing glucose absorption in muscular, fatty and hepatic tissues, thus considerably reducing insulin resistance (extra-pancreatic attachment point). Glyburide 0-13 insulin Homo sapiens 25-32 8960854-9 1996 Two thirds of the patients allocated to glibenclamide treatment had to be given insulin due to inadequate glycaemic control. Glyburide 40-53 insulin Homo sapiens 80-87 7589855-0 1995 An ATP-sensitive Cl- channel current that is activated by cell swelling, cAMP, and glyburide in insulin-secreting cells. Glyburide 83-92 insulin Homo sapiens 96-103 9026680-7 1996 These results indicate that in NIDDM patients with secondary failure to glyburide bed-time ultralent insulin administration is a better tool to improve the post prandial plasma glucose. Glyburide 72-81 insulin Homo sapiens 101-108 8773160-14 1996 Insulin concentrations were increased during the glyburide plus aspirin treatment. Glyburide 49-58 insulin Homo sapiens 0-7 8200602-6 1994 Glibenclamide can be used either alone to treat type 2 diabetes or in combination with other oral antidiabetics or insulin. Glyburide 0-13 insulin Homo sapiens 115-122 8082525-8 1994 The mean relative insulin increase (1-h postprandial) was 1.5 in the placebo group, 1.1 in the acarbose group, and 2.5 in the glibenclamide group. Glyburide 126-139 insulin Homo sapiens 18-25 8082525-15 1994 Because postprandial insulin increase has been shown to be associated with increased risk for cardiovascular disease, acarbose, which lowers pp increase, may be superior to glibenclamide, which elevates postprandial insulin increase. Glyburide 173-186 insulin Homo sapiens 216-223 8846678-0 1995 More uniform diurnal blood glucose control and a reduction in daily insulin dosage on addition of glibenclamide to insulin in type 1 diabetes mellitus: role of enhanced insulin sensitivity. Glyburide 98-111 insulin Homo sapiens 68-75 8846678-6 1995 Therefore, it is apparent that the addition of glibenclamide to insulin reduces daily insulin dosage and renders a greater uniformity to diurnal blood glucose control, most probably secondary to enhancement of insulin sensitivity. Glyburide 47-60 insulin Homo sapiens 86-93 8846678-6 1995 Therefore, it is apparent that the addition of glibenclamide to insulin reduces daily insulin dosage and renders a greater uniformity to diurnal blood glucose control, most probably secondary to enhancement of insulin sensitivity. Glyburide 47-60 insulin Homo sapiens 86-93 7988301-1 1994 OBJECTIVE: To assess the hypoglycemic effect and the insulin-releasing effect of the main glyburide (glibenclamide) metabolites 4-trans-hydroxy-glibenclamide (M1) and 3-cis-hydroxy-glibenclamide (M2) in humans. Glyburide 90-99 insulin Homo sapiens 53-60 7988301-1 1994 OBJECTIVE: To assess the hypoglycemic effect and the insulin-releasing effect of the main glyburide (glibenclamide) metabolites 4-trans-hydroxy-glibenclamide (M1) and 3-cis-hydroxy-glibenclamide (M2) in humans. Glyburide 101-114 insulin Homo sapiens 53-60 7988301-7 1994 Serum insulin levels were significantly increased by Gb as well as by M1 and M2. Glyburide 53-55 insulin Homo sapiens 6-13 8403805-7 1993 During potassium channel blocking with glibenclamide the insulin release was more enhanced in patients than in control subjects. Glyburide 39-52 insulin Homo sapiens 57-64 8123030-0 1994 Glyburide enhances insulin gene expression and glucose-induced insulin release in isolated rat islets. Glyburide 0-9 insulin Homo sapiens 19-26 8123030-0 1994 Glyburide enhances insulin gene expression and glucose-induced insulin release in isolated rat islets. Glyburide 0-9 insulin Homo sapiens 63-70 8123030-3 1994 Incubation with glyburide (500 ng/ml) significantly increased insulin release without affecting the insulin content. Glyburide 16-25 insulin Homo sapiens 62-69 8123030-4 1994 The PPI mRNA level was not increased after incubation for 1 h but was increased after incubation for 20 h. Incubation with 5 ng/ml of glyburide for 1 h or 20 h had no effect on the content or release of insulin, but incubation with 5 ng/ml of glyburide for 20 h significantly increased the PPI mRNA level and enhanced insulin release induced by 11 mM glucose. Glyburide 134-143 insulin Homo sapiens 318-325 8123030-5 1994 These results suggest that a high concentration of glyburide stimulates insulin release directly, while a low concentration of glyburide increases the PPI mRNA level and may thereby enhance glucose-induced insulin release. Glyburide 51-60 insulin Homo sapiens 72-79 8123030-5 1994 These results suggest that a high concentration of glyburide stimulates insulin release directly, while a low concentration of glyburide increases the PPI mRNA level and may thereby enhance glucose-induced insulin release. Glyburide 127-136 insulin Homo sapiens 206-213 8112188-2 1994 OBJECTIVE: To examine the long-term (15 months) effects on glycemic control and insulin secretion of glipizide and glyburide treatment in patients with non-insulin-dependent diabetes mellitus (NIDDM). Glyburide 115-124 insulin Homo sapiens 80-87 8112188-5 1994 However, both glipizide and glyburide achieved and maintained lowered postprandial glucose levels and increased fasting and postprandial insulin levels compared with placebo. Glyburide 28-37 insulin Homo sapiens 137-144 8112188-6 1994 CONCLUSIONS: Both glipizide and glyburide may achieve and maintain glycemic reduction and stimulation of insulin secretion during long-term treatment. Glyburide 32-41 insulin Homo sapiens 105-112 1611155-11 1992 The average daily insulin dose rose significantly in the glyburide but not the placebo group compared with baseline. Glyburide 57-66 insulin Homo sapiens 18-25 8378743-0 1993 Does glibenclamide influence the clearance of insulin and glucose uptake in patients with type 2 diabetes mellitus? Glyburide 5-18 insulin Homo sapiens 46-53 8378743-3 1993 The aim of this study was to investigate whether glibenclamide affects clearance of insulin in Type 2 diabetic patients. Glyburide 49-62 insulin Homo sapiens 84-91 8511023-8 1993 In conclusion, in nondiabetic, hyperinsulinemic, thalassemic patients, chronic glyburide therapy normalizes insulin responses to oral glucose. Glyburide 79-88 insulin Homo sapiens 36-43 8511023-4 1993 Plasma insulin responses were markedly increased before glyburide therapy (area under insulin response curve 86 +/- 15 and 96 +/- 15 versus 40 +/- 5 nmol/min/L in normal controls, p < 0.001). Glyburide 56-65 insulin Homo sapiens 86-93 8511023-5 1993 However, insulin responses to glucose fell significantly after 3 mo of glyburide (to 52 +/- 7 nmol/min/L, p < 0.05 versus pretreatment) and were normalized after 12 mo (42 +/- 7 nmol/min/L, p = NS versus controls). Glyburide 71-80 insulin Homo sapiens 9-16 8511023-6 1993 The rate of insulin-stimulated glucose metabolism during euglycemic insulin clamps (40 mU/m2/min) was low in the patients before treatment (163 +/- 10 versus 215 +/- 17 mg/m2/min in controls, p < 0.05) and increased to 205 +/- 30 mg/m2/min after 3 mo of glyburide. Glyburide 257-266 insulin Homo sapiens 12-19 8454937-0 1993 Insulin and IGF1 receptor function among type II diabetic responders and nonresponders to glyburide. Glyburide 90-99 insulin Homo sapiens 0-7 8454937-7 1993 Iodine 125-labeled insulin binding to intact erythrocytes tended to be higher among responders both before and after glyburide. Glyburide 117-126 insulin Homo sapiens 19-26 8201916-7 1993 The dose of insulin was decreased gradually until its replacement by chloropropamide in 1967 and glibenclamide in 1970. Glyburide 97-110 insulin Homo sapiens 12-19 8201916-14 1993 Insulin levels rose moderately after stimulation with glucagon, and with glibenclamide, with simultaneous marked decrease in glycemia. Glyburide 73-86 insulin Homo sapiens 0-7 1289019-5 1992 A further improvement in metabolic control was observed in both groups after the introduction of GL; the mean reduction in glycosylated HbA1c was 1.4% for BTI and 0.7% for MI (p < 0.01 and 0.05, respectively), In conclusion, a subgroup of poorly controlled elderly Type 2 diabetic patients showed an improvement in metabolic control after a single injection of insulin despite discontinuation of maximal doses of oral antidiabetic agents. Glyburide 97-99 insulin Homo sapiens 364-371 1611155-14 1992 Several patients experienced dramatic improvements in glycemic parameters after the addition of glyburide to their insulin regimens. Glyburide 96-105 insulin Homo sapiens 115-122 1611155-15 1992 CONCLUSIONS: Improvements were observed in the FBG and Hb A1c measurements of this heterogeneous population of patients with type I diabetes after the addition of glyburide to their insulin regimens. Glyburide 163-172 insulin Homo sapiens 182-189 1908182-1 1991 The effect of glibenclamide treatment on insulin action in isolated fat cells was studied in eight moderately obese patients with non-insulin-dependent diabetes mellitus (NIDDM). Glyburide 14-27 insulin Homo sapiens 41-48 1611644-5 1992 Because of its ability to enhance target tissue insulin action, glyburide also improves glycemic control in many NIDDM patients who have previously failed therapy with other sulfonylurea agents. Glyburide 64-73 insulin Homo sapiens 48-55 1547684-1 1992 OBJECTIVE: TO investigate the effects of the addition of glyburide to the regimen of insulin-treated non-insulin-dependent diabetes mellitus (NIDDM) patients with regard to their overall insulin requirement and dosage schedule and to assess persistence of these effects. Glyburide 57-66 insulin Homo sapiens 85-92 1547684-6 1992 RESULTS: Insulin requirements in the glyburide group decreased by 29 U at 14 wk compared with 9 U in the placebo group (P less than 0.05). Glyburide 37-46 insulin Homo sapiens 9-16 1547684-8 1992 The mean +/- SD reduction in insulin requirement in the glyburide group was relatively constant (25 +/- 10 U) and was not related to premedication insulin requirement. Glyburide 56-65 insulin Homo sapiens 29-36 1547684-10 1992 CONCLUSIONS: Glyburide reduces insulin requirements for 20 wk of combination therapy in NIDDM patients. Glyburide 13-22 insulin Homo sapiens 31-38 1547684-11 1992 Patients whose initial insulin requirement is less than or equal to 25 U have a 50% chance of achieving equivalent glycemic control on glyburide alone. Glyburide 135-144 insulin Homo sapiens 23-30 1954808-1 1991 OBJECTIVE: To examine the relationship between plasma glyburide concentrations (0, 50, 100, 200, 400, and 800 nM) and the insulin response and glucose metabolism during euglycemic (4.6 +/- 0.1 mM) and hyperglycemic (11.6 +/- 0.2 mM) conditions. Glyburide 54-63 insulin Homo sapiens 122-129 1611644-3 1992 In comparison with the first-generation sulfonylureas, glyburide is at least as effective, has a lower incidence of side effects, and may enhance postreceptor insulin activity to a greater degree. Glyburide 55-64 insulin Homo sapiens 159-166 1611644-4 1992 Glyburide can improve glycemic control, as evidenced by reduced fasting blood glucose concentrations and glycohemoglobin levels, without the inconvenience of insulin injections, the higher plasma insulin concentrations, and the additional training required to administer insulin. Glyburide 0-9 insulin Homo sapiens 196-203 1611644-4 1992 Glyburide can improve glycemic control, as evidenced by reduced fasting blood glucose concentrations and glycohemoglobin levels, without the inconvenience of insulin injections, the higher plasma insulin concentrations, and the additional training required to administer insulin. Glyburide 0-9 insulin Homo sapiens 196-203 1628875-12 1992 Among the various drugs interfering with insulin secretion, sulfonylureas, such as tolbutamide and glibenclamide, directly inhibit ATP-dependent K+ channels in the B cell membrane and thereby initiate insulin release. Glyburide 99-112 insulin Homo sapiens 41-48 1916009-1 1991 A 41-year old male with insulin-dependent diabetes mellitus previously unsuccessfully treated with a controlled diet and glibenclamide, and subsequently with increasing insulin doses (5 and 20 IU/day) experienced polyuria, glycosuria and loss of weight. Glyburide 121-134 insulin Homo sapiens 24-31 1902411-8 1991 Glibenclamide added to the diet further decreased fasting glycemia by improving in vivo insulin action and reduced the magnitude of day-time elevation of plasma glucose by enhancing endogenous insulin secretion. Glyburide 0-13 insulin Homo sapiens 88-95 1847815-7 1991 These findings suggest that glyburide-induced increases in PI hydrolysis account, at least in part, for its acute stimulatory effect on insulin output and its ability to sensitize islets to subsequent stimulation. Glyburide 28-37 insulin Homo sapiens 136-143 2171690-8 1990 Treatment with glibenclamide seems to reduce serum immunoreactive insulin levels, microsomal enzyme function and NADPH generating enzyme activities in genetically obese mice. Glyburide 15-28 insulin Homo sapiens 66-73 1904820-2 1991 The rise in serum insulin levels persisted longer after glibenclamide. Glyburide 56-69 insulin Homo sapiens 18-25 1904820-4 1991 It is concluded that glibenclamide is able to maintain a more prolonged increase in serum insulin levels by inhibiting the degradation of insulin in the vascular endothelial cells of the liver. Glyburide 21-34 insulin Homo sapiens 90-97 1904820-4 1991 It is concluded that glibenclamide is able to maintain a more prolonged increase in serum insulin levels by inhibiting the degradation of insulin in the vascular endothelial cells of the liver. Glyburide 21-34 insulin Homo sapiens 138-145 2122177-5 1990 After glyburide treatment, the mean active glycogen synthase increased by 39% (P less than .05) above the fasting value during the high-dose insulin infusion. Glyburide 6-15 insulin Homo sapiens 141-148 2122177-7 1990 Changes of insulin-stimulated active glycogen synthase associated with glyburide treatment correlated with changes in total body glucose disposal rates (r = .70, P less than .05) during euglycemic clamps. Glyburide 71-80 insulin Homo sapiens 11-18 2122177-8 1990 We conclude that glyburide treatment of subjects with NIDDM is associated with an increase in insulin action in vivo and concomitantly with improved insulin action on skeletal muscle glycogen synthase. Glyburide 17-26 insulin Homo sapiens 94-101 2122177-8 1990 We conclude that glyburide treatment of subjects with NIDDM is associated with an increase in insulin action in vivo and concomitantly with improved insulin action on skeletal muscle glycogen synthase. Glyburide 17-26 insulin Homo sapiens 149-156 2117385-2 1990 The early studies, which were performed in patients receiving concomitant insulin therapy, may have underestimated the true effect of glyburide on insulin secretion. Glyburide 134-143 insulin Homo sapiens 147-154 2117385-4 1990 The effects of glyburide on insulin secretory rates calculated from plasma C-peptide levels were recently evaluated using individually derived C-peptide kinetic parameters and a validated open two-compartment model of peripheral C-peptide kinetics. Glyburide 15-24 insulin Homo sapiens 28-35 2117385-8 1990 During that time, insulin secretion rates increased by 221 percent in response to glyburide. Glyburide 82-91 insulin Homo sapiens 18-25 2117385-10 1990 In the patients receiving glyburide, the sluggish insulin secretory response to breakfast persisted, and the insulin secretory response during the hyperglycemic clamping was less than the response normally seen in nondiabetic subjects. Glyburide 26-35 insulin Homo sapiens 50-57 2117385-10 1990 In the patients receiving glyburide, the sluggish insulin secretory response to breakfast persisted, and the insulin secretory response during the hyperglycemic clamping was less than the response normally seen in nondiabetic subjects. Glyburide 26-35 insulin Homo sapiens 109-116 2117386-3 1990 Glyburide, one of the second-generation sulfonylureas, decreases glucose production and enhances insulin action in the liver. Glyburide 0-9 insulin Homo sapiens 97-104 2117386-5 1990 The effect of glyburide on the insulin-signaling mechanism(s) is distal to the insulin binding site of the alpha-subunit of the insulin receptor and the tyrosine kinase activation site of the beta-subunit. Glyburide 14-23 insulin Homo sapiens 31-38 2117386-5 1990 The effect of glyburide on the insulin-signaling mechanism(s) is distal to the insulin binding site of the alpha-subunit of the insulin receptor and the tyrosine kinase activation site of the beta-subunit. Glyburide 14-23 insulin Homo sapiens 79-86 2117386-5 1990 The effect of glyburide on the insulin-signaling mechanism(s) is distal to the insulin binding site of the alpha-subunit of the insulin receptor and the tyrosine kinase activation site of the beta-subunit. Glyburide 14-23 insulin Homo sapiens 79-86 2117387-4 1990 Glyburide is generally thought to exert two major actions: stimulation of pancreatic insulin secretion and enhancement of insulin action in hepatic and extrahepatic tissues. Glyburide 0-9 insulin Homo sapiens 85-92 2117389-0 1990 Effects of glyburide on in vivo insulin-mediated glucose disposal. Glyburide 11-20 insulin Homo sapiens 32-39 2117389-6 1990 In protocol 1, glyburide significantly improved insulin sensitivity (p less than 0.01) and insulin secretion (p less than 0.01) in the NIDDM patients. Glyburide 15-24 insulin Homo sapiens 48-55 2117389-8 1990 Insulin sensitivity also improved in the young healthy control subjects after glyburide therapy (6.5 +/- 0.5 to 7.6 +/- 0.7 mg/kg.min; p less than 0.05). Glyburide 78-87 insulin Homo sapiens 0-7 2119677-2 1990 In a single-blind, placebo controlled study the influence of tenoxicam on responses of glucose, insulin and C-peptide to oral doses of glucose and glibenclamide was examined in 16 healthy male volunteers. Glyburide 147-160 insulin Homo sapiens 108-117 2123183-10 1990 This study shows that addition of glibenclamide to insulin treatment is advantageous in NIDDM patients showing secondary failure to OHA. Glyburide 34-47 insulin Homo sapiens 51-58 1660613-2 1991 Using HIT cells as a model system, we have established an extremely close correlation between the affinity of binding of glyburide and its analog, iodoglyburide, and the activation of various steps in stimulus-secretion coupling--inhibition of 86Rb+ efflux, increase in [Ca2+]i resulting from gating of voltage-gated calcium channels by cell depolarization, and the exocytosis of insulin. Glyburide 121-130 insulin Homo sapiens 380-387 2126639-10 1990 We conclude from our own experience and the literature that combined insulin-glibenclamide therapy is an efficient and compliant therapeutic regimen. Glyburide 77-90 insulin Homo sapiens 69-76 2125460-11 1990 Glibenclamide produced significant increases in insulin concentrations compared with drug-free periods (P less than 0.01). Glyburide 0-13 insulin Homo sapiens 48-55 2115686-9 1990 The combination of glibenclamide and insulin (administered with the Novo Pen injector) is a safe and effective form of therapy in secondary failure of sulfonylurea, and is well accepted due to the mild start into insulin therapy. Glyburide 19-32 insulin Homo sapiens 213-220 2110711-3 1990 A statistically significant decrease of blood glucose and glycosylated hemoglobin values was found under the combination of glibenclamide-phenformin contained in the same tablet in contrast to the values obtained with the treatment with glibenclamide, gliclazide, chlorpropamide, combination of glibenclamide and biguanides, metformin, and insulin. Glyburide 124-137 insulin Homo sapiens 340-347 2171690-5 1990 Glibenclamide reduced blood glucose and plasma insulin levels indicating improved insulin sensitivity in the mice. Glyburide 0-13 insulin Homo sapiens 47-54 2171690-5 1990 Glibenclamide reduced blood glucose and plasma insulin levels indicating improved insulin sensitivity in the mice. Glyburide 0-13 insulin Homo sapiens 82-89 35261444-1 2022 Insulin is recommended as first-line pharmacologic therapy for gestational diabetes (GDM); however, glyburide and metformin are often used. Glyburide 100-109 insulin Homo sapiens 0-7 34907818-9 2022 Glyburide is behind metformin and insulin, and more RCTs are needed to verify its safety. Glyburide 0-9 insulin Homo sapiens 34-41 2499443-2 1989 Glyburide (15 mg/day) or placebo was added to the treatment regimen of 31 insulin-treated type II (non-insulin-dependent) diabetic subjects. Glyburide 0-9 insulin Homo sapiens 74-81 2559356-0 1989 Insulin and IGF-I receptors in neuroblastoma cells: increases in mRNA and binding produced by glyburide. Glyburide 94-103 insulin Homo sapiens 0-7 2505990-0 1989 Low-dose bedtime NPH insulin in treatment of secondary failure to glyburide. Glyburide 66-75 insulin Homo sapiens 21-28 2504288-1 1989 Drugs which influence the electrical activity of insulin-secreting B cells of mammalian islets of Langerhans by closing (tolbutamide and glibenclamide) or opening (diazoxide) ATP-sensitive potassium channels were applied to the ventricular muscle of the rat. Glyburide 137-150 insulin Homo sapiens 49-56 2524334-5 1989 Mean (+/- SE) insulin-mediated glucose metabolic clearance rate was evaluated during glucose clamp studies, and was significantly higher (p less than 0.001) after glibenclamide therapy at steady-state insulin levels of approximately 10 mU l-1 (53 +/- 3 vs 38 +/- 2 ml-2 min-1) and approximately 70 mU l-1 (78 +/- 9 vs 55 +/- 6 ml m-2 min-1). Glyburide 163-176 insulin Homo sapiens 14-21 2524334-5 1989 Mean (+/- SE) insulin-mediated glucose metabolic clearance rate was evaluated during glucose clamp studies, and was significantly higher (p less than 0.001) after glibenclamide therapy at steady-state insulin levels of approximately 10 mU l-1 (53 +/- 3 vs 38 +/- 2 ml-2 min-1) and approximately 70 mU l-1 (78 +/- 9 vs 55 +/- 6 ml m-2 min-1). Glyburide 163-176 insulin Homo sapiens 201-208 2524334-6 1989 Hepatic glucose production was also lower following glibenclamide treatment at both the lower (56 +/- 5 vs 68 +/- 5 mg m-2 min-1) and higher 22 +/- 4 vs 32 +/- 6 mg m-2 min-1) insulin levels. Glyburide 52-65 insulin Homo sapiens 176-183